The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

The study is divided into two phases. In the first phase, participants will receive either PLS240 or a placebo to compare the effects. This phase is designed to see if PLS240 can effectively lower PTH levels by at least 30%. In the second phase, which is open-label, all participants will receive PLS240 to further assess its long-term safety. Participants will receive the medication through an intravenous injection, which means it will be administered directly into a vein using a pre-filled syringe.

The trial will last for a maximum of 53 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. These check-ups will include laboratory tests, physical exams, and monitoring of vital signs. The goal is to ensure the treatment is both effective and safe for individuals with secondary hyperparathyroidism undergoing hemodialysis.

Table of Contents

• Overview of the studies
• Who the trials include
• What the trials measure
• Trial phases and status
• Study details by trial
• What the results could show

Overview of the studies

These clinical trials are studying ZILUCOPLAN in people with generalized myasthenia gravis (gMG), a disease that causes muscle weakness in several parts of the body.^[1][2]

The available trials focus on later stages of research, with Phase 3 and Phase 4 studies listed in the source data.^[1][2]

Across the trials, researchers are mainly looking at safety, long-term tolerability, and in some studies how ZILUCOPLAN behaves in the body and how it affects disease-related tests.^[1][2]

Who the trials include

One trial is for pediatric participants, meaning children and adolescents, and it includes patients from 2 to under 18 years of age with gMG.^[2]

Another pediatric study follows children who already took part in a previous ZILUCOPLAN study, so it is designed as a follow-up for earlier participants.^[1]

The adult extension study includes people with gMG who have already completed a qualifying ZILUCOPLAN clinical study.^[3]

One additional study listed in the data is a broader myasthenia gravis study that includes ZILUCOPLAN among many other treatments, but its main focus is not ZILUCOPLAN alone.^[4]

What the trials measure

The pediatric long-term safety study measures treatment-emergent adverse events (health problems that appear after treatment starts), serious adverse events, treatment stopping because of side effects, and infections.^[1]

The pediatric Phase 4 study measures plasma concentrations of ZILUCOPLAN, which means how much of the study drug is found in the blood, at Week 4.^[2]

That same study also measures change from baseline in sheep red blood cell (sRBC) lysis and complement component 5 (C5) levels at Week 4, which are laboratory tests used in the study to track biological effects.^[2]

The adult extension study measures the incidence of TEAEs, which helps show how often new side effects happen during follow-up treatment.^[3]

The broader study that lists ZILUCOPLAN among several treatments measures MG-ADL and QMG changes at 24 weeks in different phases, which are scores used to track daily function and muscle weakness in myasthenia gravis.^[4]

Trial phases and status

The pediatric safety follow-up study is in Phase 3 and is marked Authorised with an enrollment of 10 participants.^[1]

The pediatric study of blood levels and biological effects is in Phase 4, also marked Authorised, with an enrollment of 10 participants.^[2]

The adult long-term extension study is in Phase 3, is Authorised, and has a planned enrollment of 190 participants.^[3]

The broader study that includes ZILUCOPLAN alongside other treatments is listed as Phase 4, Authorised, with 66 participants.^[4]

Study details by trial

NCT06435312 is a long-term safety study in children with gMG who already joined a previous ZILUCOPLAN study.^[1] The brief summary says it is designed to assess safety and tolerability over an extra 52 weeks of daily subcutaneous treatment.^[1]

NCT06055959 studies how ZILUCOPLAN moves through the body over time and how safe it is in children with gMG.^[2] Its brief summary also says it looks at both pharmacokinetics and pharmacodynamics, which means it studies drug levels in the body and the body’s response to treatment.^[2]

NCT04225871 is an adult extension study that looks at long-term safety and tolerability in people with gMG who finished a qualifying ZILUCOPLAN study.^[3] Its only listed primary outcome is the incidence of TEAEs.^[3]

NCT06193889 is a broader study of anti-CD19 chimeric antigen receptor T-cell therapy in generalized myasthenia gravis, and it lists ZILUCOPLAN among several study drugs.^[4] Its primary outcomes in the source data focus on safety, MG-ADL change, and QMG change at 24 weeks for the main study treatment being tested.^[4]

What the results could show

These trials may help show whether ZILUCOPLAN can be used safely over time in children and adults with generalized myasthenia gravis.^[1][3]

They may also help researchers understand whether the treatment reaches the blood in expected amounts and whether it changes study markers linked to disease activity.^[2]

Because the studies are in later phases, they are especially focused on real patient experience, follow-up safety, and longer-term observation rather than early proof-of-concept testing.^[1][2][3]

Table of Contents

• What is Testosterone Undecanoate?
• Medical Conditions Treated
• Administration and Dosage
• Benefits and Effects
• Potential Side Effects
• Ongoing Research

What is Testosterone Undecanoate?

Testosterone Undecanoate is a form of testosterone replacement therapy used to treat various conditions related to low testosterone levels in men. It’s also known by brand names such as Nebido, Aveed, and Andriol^[1][2]. This medication is designed to mimic the body’s natural testosterone production, helping to alleviate symptoms associated with low testosterone levels.

Medical Conditions Treated

Testosterone Undecanoate is primarily used to treat the following conditions:

• Male Hypogonadism: This is a condition where the body doesn’t produce enough testosterone. It can be caused by problems with the testicles or the pituitary gland^[1].
• Delayed Puberty: In some cases, it may be used to help start puberty in boys who are late in developing^[3].
• Muscle Loss: It can help prevent muscle loss in certain situations, such as after bariatric surgery^[4].

Administration and Dosage

Testosterone Undecanoate is typically administered in one of two ways:

1. Intramuscular Injection: This is the most common form. It’s usually given as a deep injection into the buttock muscle. The typical dose is 1000 mg, given at intervals of 10-14 weeks^[1].
2. Oral Capsules: In some cases, it may be given as oral capsules. However, this form is less common and may require more frequent dosing^[2].

The exact dosage and frequency will be determined by your doctor based on your individual needs and response to the treatment.

Benefits and Effects

Testosterone Undecanoate can have several positive effects on the body:

• Improved Sexual Function: It can help improve libido (sex drive) and erectile function^[1].
• Increased Muscle Mass and Strength: It can help build and maintain muscle mass, which is particularly beneficial for men experiencing muscle loss^[4].
• Improved Bone Density: Testosterone plays a role in maintaining bone strength, and replacement therapy can help prevent bone loss^[4].
• Better Mood and Quality of Life: Some men report improved mood and overall quality of life when their testosterone levels are normalized^[1].

Potential Side Effects

While Testosterone Undecanoate can be beneficial, it’s important to be aware of potential side effects:

• Increased Red Blood Cell Count: This can potentially increase the risk of blood clots^[4].
• Prostate Changes: There may be an increased risk of prostate enlargement or prostate cancer, which is why regular prostate exams are important during treatment^[4].
• Acne and Oily Skin: Some men may experience increased acne or oilier skin^[5].
• Sleep Apnea: In some cases, testosterone therapy may worsen existing sleep apnea^[4].

It’s crucial to discuss all potential risks and benefits with your healthcare provider before starting treatment.

Ongoing Research

Researchers are continually studying Testosterone Undecanoate to better understand its effects and potential uses. Some areas of ongoing research include:

• Use in Bariatric Surgery Patients: Studies are investigating whether testosterone therapy can help prevent muscle loss in men undergoing weight loss surgery^[4].
• Effects on Physical Performance: Research is being conducted on how testosterone therapy might improve physical performance during intense activities, such as military operations^[6].
• Treatment of Non-alcoholic Steatohepatitis (NASH): Some studies are exploring whether testosterone therapy could help improve liver health in men with NASH, a type of fatty liver disease^[7].

These ongoing studies may lead to new uses for Testosterone Undecanoate in the future, potentially benefiting more patients with various health conditions.

Table of Contents

• What is Octreotide Acetate?
• Conditions Treated with Octreotide Acetate
• How Octreotide Acetate Works
• How Octreotide Acetate is Administered
• Ongoing Research and Clinical Trials
• Potential Side Effects and Safety Considerations

What is Octreotide Acetate?

Octreotide Acetate is a medication that belongs to a class of drugs called somatostatin analogs. It is also known by other names such as Sandostatin, SMS995, and Siroctid ^[1][2][3]. This medication is designed to mimic the effects of somatostatin, a natural hormone in your body that regulates various functions, particularly in the digestive system and certain glands.

Conditions Treated with Octreotide Acetate

Octreotide Acetate is used to treat several medical conditions, including:

• Acromegaly: A hormonal disorder that results from the production of too much growth hormone, leading to abnormal growth of body tissues ^[1][4]
• Neuroendocrine Tumors (NETs): Rare tumors that can occur in various parts of the body, particularly in the digestive system or lungs ^[5]
• Carcinoid Syndrome: A group of symptoms associated with certain types of NETs ^[6]
• Pancreatic Fistula: A complication that can occur after pancreatic surgery ^[3]
• Diarrhea associated with certain medications: For example, diarrhea caused by mycophenolate mofetil, an immunosuppressant drug ^[7]

How Octreotide Acetate Works

Octreotide Acetate works by mimicking the action of somatostatin in the body. It helps to:

• Reduce the production of certain hormones, such as growth hormone and insulin-like growth factor 1 (IGF-1) in acromegaly patients ^[1]
• Slow down the growth of tumors in patients with neuroendocrine tumors ^[5]
• Control symptoms associated with carcinoid syndrome, such as flushing and diarrhea ^[6]
• Reduce pancreatic secretions, which can help in preventing or treating pancreatic fistulas ^[3]

How Octreotide Acetate is Administered

Octreotide Acetate can be administered in several ways:

• Short-acting injections: Given subcutaneously (under the skin) multiple times a day ^[5]
• Long-acting release (LAR) formulations: Given as intramuscular injections every 28 days ^[8]
• Implants: Subcutaneous implants that release the medication over an extended period ^[4]
• Experimental formulations: Such as Debio 4126, a 12-week prolonged-release formulation being studied in clinical trials ^[6]

Ongoing Research and Clinical Trials

Researchers are continuously studying Octreotide Acetate to understand its effects better and explore new potential uses. Some areas of ongoing research include:

• Its impact on the immune system in patients with neuroendocrine tumors ^[5]
• Long-term safety and efficacy in treating acromegaly ^[8]
• Comparison with other medications like somatostatin in preventing pancreatic fistulas after surgery ^[3]
• Its potential use in treating polycystic kidney disease ^[9]
• Its effectiveness in treating advanced liver cancer ^[10]

Potential Side Effects and Safety Considerations

Like all medications, Octreotide Acetate can cause side effects. Common side effects may include:

• Gastrointestinal symptoms such as diarrhea, nausea, or abdominal pain
• Injection site reactions
• Changes in blood sugar levels
• Gallbladder problems

It’s important to note that the safety and tolerability of Octreotide Acetate are continually being evaluated in clinical trials ^[6]. Your healthcare provider will monitor you closely while you’re on this medication and adjust the dosage as needed to minimize side effects while maximizing benefits.

Table of Contents

• What is Metyrapone?
• How Metyrapone Works
• Conditions Treated with Metyrapone
• Dosage and Administration
• Potential Side Effects
• Ongoing Research and Future Applications

What is Metyrapone?

Metyrapone, also known by its brand name Metopirone, is a medication that affects the production of cortisol in your body^[1]. Cortisol is often called the “stress hormone” because it helps your body respond to stress. However, too much cortisol can lead to various health problems.

This drug is approved by the U.S. Food and Drug Administration (FDA) for diagnosing adrenal insufficiency, a condition where your body doesn’t produce enough cortisol^[2]. In Europe, it’s also approved for treating a condition called Cushing’s syndrome, which involves having too much cortisol in your body^[3].

How Metyrapone Works

Metyrapone works by blocking an enzyme in your body called 11β-hydroxylase. This enzyme is important in the final step of cortisol production. By inhibiting this enzyme, metyrapone reduces the amount of cortisol your body produces^[4].

In addition to lowering cortisol, metyrapone can also affect other hormones in your body. It may increase the levels of hormones that come before cortisol in the production process, such as 11-deoxycortisol^[5].

Conditions Treated with Metyrapone

Metyrapone is used or being studied for several conditions related to cortisol imbalance:

• Cushing’s Syndrome: This is a condition where your body produces too much cortisol. Metyrapone can help lower cortisol levels in these patients^[3].
• Mild Autonomous Cortisol Secretion (MACS): This is a milder form of cortisol excess. Research is ongoing to see if metyrapone can help control symptoms in these patients^[2].
• Depression: Some studies are looking at whether metyrapone, when added to regular antidepressant treatment, might help improve symptoms in people with depression who haven’t responded well to standard treatments^[4][5].
• Metabolic Syndrome and Obesity: Researchers are investigating whether short-term use of metyrapone might improve how the body responds to sugar intake in people with metabolic syndrome and obesity^[6].

Dosage and Administration

The dosage and how you take metyrapone can vary depending on why you’re using it. Here are some examples from clinical studies:

• For Cushing’s Syndrome: Doses may range from 250 mg to 6000 mg per day, taken orally in divided doses^[3].
• For research in depression: Some studies have used 500 mg twice daily for 3 weeks^[7].
• For research in metabolic syndrome: A study used 15 mg per kilogram of body weight, given twice over 12 hours^[6].

Always follow your doctor’s instructions on how to take metyrapone. Never adjust your dose without consulting your healthcare provider.

Potential Side Effects

Like all medications, metyrapone can cause side effects. Some potential side effects may include:

• Nausea or vomiting
• Dizziness or lightheadedness
• Headache
• Abdominal pain
• Changes in blood pressure

In some cases, metyrapone might lower cortisol levels too much, leading to symptoms of adrenal insufficiency. These could include fatigue, weakness, and dizziness. If you experience these symptoms, contact your doctor immediately^[2].

Ongoing Research and Future Applications

Researchers are exploring new ways metyrapone might be used to help patients:

• Depression Treatment: Studies are looking at whether adding metyrapone to standard antidepressants might help people with depression who haven’t responded well to usual treatments^[4][5].
• Addiction Treatment: Some research is investigating whether metyrapone, possibly in combination with other drugs, might help in treating addictions like cocaine use disorder or tobacco use disorder^[1].
• Metabolic Health: Scientists are studying whether short-term use of metyrapone might improve how the body handles sugar in people with metabolic syndrome and obesity^[6].

It’s important to note that these are areas of ongoing research. Metyrapone is not currently approved for these uses, and more studies are needed to determine if it might be helpful in these conditions.

Table of Contents

• What is Ixekizumab?
• How Does Ixekizumab Work?
• Conditions Treated with Ixekizumab
• How is Ixekizumab Administered?
• Effectiveness of Ixekizumab
• Potential Side Effects
• Ongoing Research and Potential New Uses

What is Ixekizumab?

Ixekizumab, also known by its brand name Taltz, is a prescription medication used to treat several inflammatory conditions^[1]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules designed to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on specific cells^[2].

How Does Ixekizumab Work?

Ixekizumab works by targeting and blocking a specific protein in your body called interleukin 17A (IL-17A). This protein is involved in causing inflammation in various conditions. By inhibiting IL-17A, ixekizumab helps reduce inflammation and alleviate symptoms associated with certain inflammatory diseases^[2].

Conditions Treated with Ixekizumab

Ixekizumab is approved to treat several conditions, including:

• Plaque Psoriasis: A chronic skin condition characterized by red, scaly patches on the skin^[5].
• Psoriatic Arthritis: A type of inflammatory arthritis that affects some people with psoriasis^[6].
• Generalized Pustular Psoriasis: A rare and severe form of psoriasis characterized by widespread redness and pustules on the skin^[7].
• Erythrodermic Psoriasis: A severe form of psoriasis that affects most of the body surface^[7].

Additionally, researchers are investigating its potential use in other conditions such as:

• Idiopathic Subglottic Stenosis: A rare condition causing narrowing of the airway below the vocal cords^[1].
• Bullous Pemphigoid: An autoimmune blistering disease of the skin^[2].
• Pityriasis Rubra Pilaris: A rare inflammatory skin disease^[3].
• Treatment-Resistant Depression: A form of depression that doesn’t respond to standard treatments^[8].
• Type 1 Diabetes: An autoimmune condition affecting insulin production^[9].

How is Ixekizumab Administered?

Ixekizumab is administered as a subcutaneous (under the skin) injection. The dosing schedule can vary depending on the condition being treated, but generally follows this pattern:

• An initial higher dose (usually 160 mg) at the start of treatment.
• Followed by regular doses (usually 80 mg) every 2 or 4 weeks, depending on the condition and treatment phase^[1][4].

Your healthcare provider will determine the appropriate dosing schedule for your specific condition and needs.

Effectiveness of Ixekizumab

Clinical trials have shown ixekizumab to be effective in treating its approved conditions. For example:

• In plaque psoriasis, many patients achieve significant improvement in skin clearance, measured by scales such as the Psoriasis Area and Severity Index (PASI)^[5].
• For psoriatic arthritis, ixekizumab has shown to improve joint symptoms and physical function^[6].
• In generalized pustular psoriasis and erythrodermic psoriasis, ixekizumab has demonstrated effectiveness in reducing disease severity^[7].

Potential Side Effects

Like all medications, ixekizumab can cause side effects. Common side effects may include:

• Injection site reactions (redness, pain, or swelling at the injection site)
• Upper respiratory infections
• Nausea
• Fungal infections

More serious side effects, though rare, can occur. These may include serious allergic reactions or increased risk of infections. Always discuss potential side effects with your healthcare provider^[2].

Ongoing Research and Potential New Uses

Researchers are continually exploring new potential uses for ixekizumab. Some areas of ongoing research include:

• Idiopathic Subglottic Stenosis: Studies are investigating whether ixekizumab can reduce the need for repeated surgeries in this rare airway condition^[1].
• Bullous Pemphigoid: Research is examining if ixekizumab can effectively treat this autoimmune blistering disease^[2].
• Treatment-Resistant Depression: Scientists are exploring whether blocking IL-17A with ixekizumab could help patients with depression that hasn’t responded to other treatments^[8].
• Type 1 Diabetes: A study is investigating if ixekizumab can help preserve insulin production in newly diagnosed type 1 diabetes patients^[9].

These studies highlight the potential versatility of ixekizumab in treating various inflammatory and autoimmune conditions. However, it’s important to note that these are still under investigation and not approved uses of the medication.

Table of Contents

• What is Crinecerfont?
• What Condition Does Crinecerfont Treat?
• How Does Crinecerfont Work?
• Clinical Trials for Crinecerfont
• Potential Benefits of Crinecerfont
• How is Crinecerfont Administered?

What is Crinecerfont?

Crinecerfont, also known by its research name NBI-74788, is a new medication being developed to treat Congenital Adrenal Hyperplasia (CAH). It is currently undergoing clinical trials to evaluate its safety and effectiveness in both adults and children with this condition^[1][2][3].

What Condition Does Crinecerfont Treat?

Crinecerfont is specifically designed to treat Congenital Adrenal Hyperplasia (CAH). CAH is a genetic disorder that affects the adrenal glands, which are small glands located on top of the kidneys. In people with CAH, the adrenal glands cannot produce certain hormones properly, particularly cortisol. This leads to an overproduction of male hormones (androgens) and can cause various health issues^[1][2][3].

How Does Crinecerfont Work?

Crinecerfont is a CRF1-receptor antagonist. This means it blocks a specific receptor in the body that is involved in the production of certain hormones. By doing so, Crinecerfont aims to reduce the overproduction of androgens (male hormones) in people with CAH. This could potentially help manage the symptoms of the condition and reduce the need for high doses of other medications currently used to treat CAH^[2][3].

Clinical Trials for Crinecerfont

Crinecerfont is currently being studied in several clinical trials:

• A Phase 2 trial in adolescents (14-17 years old) with CAH^[1]
• A Phase 3 trial in adults with classic CAH^[2]
• A Phase 3 trial in children with classic CAH^[3]

These trials are designed to evaluate the safety, effectiveness, and proper dosing of Crinecerfont in different age groups. They involve both short-term and long-term treatment periods to gather comprehensive data on the medication’s effects^[1][2][3].

Potential Benefits of Crinecerfont

Based on the clinical trials, researchers are investigating several potential benefits of Crinecerfont for people with CAH:

• Reduction in glucocorticoid dose: Crinecerfont may allow patients to reduce their daily dose of glucocorticoids, which are currently used to treat CAH but can have significant side effects when used long-term^[2][3]
• Improved hormone balance: The medication aims to reduce levels of certain hormones that are typically elevated in CAH, such as androstenedione and 17-hydroxyprogesterone^[1][2][3]
• Metabolic improvements: Researchers are studying whether Crinecerfont can help improve various metabolic factors, including insulin resistance, body weight, and fat mass^[2]
• Other potential benefits: The trials are also investigating effects on blood pressure, glucose tolerance, menstrual regularity in females, and testicular adrenal rest tumors in males^[2]

How is Crinecerfont Administered?

In the clinical trials, Crinecerfont is being administered orally (by mouth). It is given twice daily, either as a capsule or as a solution. The exact dosage and formulation may vary depending on the age of the patient and the specific trial^[1][2][3].

It’s important to note that Crinecerfont is still an investigational drug. This means it has not yet been approved by regulatory agencies like the FDA for general use. Its safety and effectiveness are still being studied, and it is only available to patients participating in clinical trials^[1][2][3].

Table of Contents

• What is Dasiglucagon?
• What Conditions Does Dasiglucagon Treat?
• How Does Dasiglucagon Work?
• How is Dasiglucagon Administered?
• Clinical Trials and Research
• Safety and Side Effects

What is Dasiglucagon?

Dasiglucagon is a new medication that belongs to a class of drugs called glucagon analogs. It is also known by the names ZP4207 and Zegalogue^[1][2]. Dasiglucagon is designed to mimic the effects of glucagon, a hormone naturally produced by the body that helps raise blood sugar levels^[3].

Unlike traditional glucagon, which can be difficult to prepare and use, dasiglucagon comes in a ready-to-use liquid form. This makes it easier and quicker to administer in emergency situations^[3].

What Conditions Does Dasiglucagon Treat?

Dasiglucagon is primarily used to treat or prevent several conditions related to blood sugar levels:

• Severe Hypoglycemia: This is a dangerous condition where blood sugar levels drop too low in people with diabetes. Dasiglucagon can quickly raise blood sugar levels in these emergency situations^[4].
• Type 1 Diabetes: While not a cure for diabetes, dasiglucagon can help manage dangerous low blood sugar episodes in people with type 1 diabetes^[5].
• Congenital Hyperinsulinism: This is a rare genetic condition where the body produces too much insulin, leading to frequent episodes of low blood sugar. Dasiglucagon is being studied as a potential treatment for children with this condition^[6].
• Post-Bariatric Hypoglycemia: Some people who have had gastric bypass surgery experience episodes of low blood sugar. Dasiglucagon is being investigated as a treatment for this condition^[7].

How Does Dasiglucagon Work?

Dasiglucagon works by mimicking the action of glucagon in the body. When blood sugar levels are too low, dasiglucagon stimulates the liver to release stored glucose (sugar) into the bloodstream. This helps to quickly raise blood sugar levels and alleviate symptoms of hypoglycemia^[3].

In clinical trials, dasiglucagon has been shown to raise blood sugar levels within 10-15 minutes after administration^[4]. This rapid action is crucial in emergency situations where quick treatment of severe hypoglycemia is necessary.

How is Dasiglucagon Administered?

Dasiglucagon is typically administered as a subcutaneous (under the skin) injection. It comes in several forms:

• Pre-filled syringe^[2]
• Auto-injector pen^[5]
• Continuous infusion pump (for certain conditions like congenital hyperinsulinism)^[8]

The dose of dasiglucagon may vary depending on the condition being treated and the patient’s age. For example, in some trials, adults received a 0.6 mg dose, while children received lower doses of 0.3 mg or 0.6 mg based on their age and weight^[2].

Clinical Trials and Research

Dasiglucagon has been the subject of numerous clinical trials to evaluate its safety and effectiveness. Some key findings from these trials include:

• Effectiveness in treating severe hypoglycemia in adults with type 1 diabetes^[4]
• Potential use in automated insulin delivery systems for preventing hypoglycemia in people with type 1 diabetes^[5]
• Promising results in treating children with congenital hyperinsulinism^[8]
• Investigation of its use in treating post-bariatric hypoglycemia^[7]

These trials have helped establish the effectiveness of dasiglucagon in various scenarios and patient populations.

Safety and Side Effects

Like all medications, dasiglucagon can cause side effects. Common side effects reported in clinical trials include:

• Nausea
• Vomiting
• Headache
• Diarrhea
• Injection site reactions (such as pain or redness)^[3]

Most side effects were reported to be mild to moderate in severity. However, as with any medication, it’s important to discuss potential risks and benefits with your healthcare provider.

Researchers have also studied the potential for dasiglucagon to cause an immune response in the body. Some patients may develop antibodies to the medication, but the clinical significance of this is still being studied^[1].

Overall, dasiglucagon represents a promising new treatment option for various conditions related to low blood sugar. Its rapid action and easy-to-use formulation make it a valuable tool in managing hypoglycemia and related conditions. As research continues, we may see expanded uses for this medication in the future.

Table of Contents

• What Carbomer 980 is in these trials
• Where Carbomer 980 was used (nasal spray, topical vehicle gel, listed product)
• Common cold: efficacy study of 1146A (Carbomer 980) nasal spray
• Healthy adults: local nasal tolerability and safety study of 1146A
• Pruritus (itch): Carbomer 980 as the vehicle gel in a topical acetaminophen study
• How outcomes were measured (symptom scores and grading scales)
• Safety monitoring: vital signs and laboratory testing
• Turner syndrome trial record: Carbomer 980 listed as a gelling agent product

What Carbomer 980 is in these trials

Carbomer 980 was used as a gel ingredient in trial products, including a nasal spray gel (1146A) and a topical vehicle gel used for comparison in an itch study.^[1][2][3]

In a European trial record, carbomer 980 is described as a substance of polymer origin and is listed as a “gelling agent” (meaning it helps form a gel texture).^[4]

Where Carbomer 980 was used (nasal spray, topical vehicle gel, listed product)

In common cold research, carbomer 980 was part of a test nasal spray gel product referred to as 1146A (carbomer 980 nasal spray gel).^[1][2]

In a pruritus (itch) proof-of-concept study, carbomer 980 was listed as the drug name for the topical vehicle gel, meaning it was the comparison gel base (not the active itch-relief drug).^[3]

In a separate European trial record (Turner syndrome), carbomer 980 appears as a medicinal product entry named “CARBOMER 980” with pharmaceutical form “EYE GEL,” and it is also labeled as a “gelling agent,” with route listed as transdermal use in that product entry.^[4]

Common cold: efficacy study of 1146A (Carbomer 980) nasal spray

A multi-center study in adults with symptoms of the common cold evaluated whether 1146A nasal spray could reduce symptom severity compared with placebo, and it also evaluated safety.^[2]

The study design was randomized, parallel-group, placebo-controlled, and double-blind.^[2]

Participants in the carbomer 980 (1146A) group used a nasal spray containing carbomer 980 gel, given as three actuations per nostril per dose, with each actuation 140 microliters (equivalent to 140 mg).^[2]

The placebo group used a reference nasal spray vehicle without carbomer 980, also given as three actuations per nostril per dose, with each actuation 140 microliters.^[2]

Healthy adults: local nasal tolerability and safety study of 1146A

A single-center study in healthy adults assessed the local nasal tolerability and safety of multiple intranasal administrations of 1146A delivered by a nasal spray applicator.^[1]

The study design was randomized, parallel-group, placebo-controlled, with an outcomes assessor masked (meaning the person judging outcomes was kept unaware of group assignment).^[1]

In the test group, participants received a nasal spray containing 0.5% carbomer 980, 4 times per day, with 3 actuations per nostril per dose and 140 microliters (140 mg) per actuation.^[1]

In the placebo comparator group, participants received a vehicle nasal spray without carbomer 980 on the same schedule and actuation volume.^[1]

Pruritus (itch): Carbomer 980 as the vehicle gel in a topical acetaminophen study

A proof-of-concept study in healthy subjects tested topical acetaminophen gels for itch relief and compared them to a vehicle gel.^[3]

The study was described as single-blinded, vehicle-controlled, and randomized, with each subject testing three acetaminophen concentrations and one vehicle treatment across two visits (one for histaminergic itch and one for non-histaminergic itch).^[3]

In this trial record, the vehicle comparator arm lists “Drug: Carbomer 980,” and the drug listing describes carbomer 980 as the topical vehicle gel (the gel base).^[3]

The gels were applied to a predefined 4×4 cm area on the ventral forearm, allowed to absorb for 30 minutes, then residual gel was removed before itch induction and sensory testing in that area.^[3]

How outcomes were measured (symptom scores and grading scales)

In the common cold efficacy study, the primary outcome was Average Nasal Symptom Score (ANSS) over days 1–4.^[2]

The nasal symptom score was the sum of runny nose, blocked nose, and sneezing, with each symptom self-rated from 0 (absent) to 3 (severe), for a total range of 0–9.^[2]

The ANSS for days 1–4 was calculated as the mean of the 4 daily nasal symptom scores across study days 1 to 4, where lower scores mean better nasal symptoms.^[2]

Secondary outcomes included ANSS over days 1–7 and Total Symptom Score (TSS) averages over days 1–4 and 1–7.^[2]

TSS added nasal symptoms plus headache, muscle ache, chills, sore throat, and cough, each rated 0–3, for a total range of 0–24.^[2]

In the nasal tolerability and safety study, the primary outcomes included the incidence of nasal mucosal changes of ≥ Grade 1B from baseline to day 8 using a nasal mucosal grading scale.^[1]

The grading scale described Grade 0 as no abnormal findings, Grade 1A as focal irritation (inflammation, erythema, or hyperemia), Grade 1B as superficial erosion, and Grade 2 as moderate erosion.^[1]

The study also tracked incidence of moderate or severe mucosal bleeding using a bleeding scale from 0 (none) to 3 (severe).^[1]

Another primary outcome was incidence of moderate or severe crusting of mucosa using a crusting scale from 0 (none) to 3 (severe).^[1]

In the pruritus study, itch intensity was measured using a visual analog scale (VAS) from 0 (no itch) to 10 (most itch imaginable) over 10 minutes after itch induction for histaminergic and non-histaminergic itch conditions.^[3]

The primary outcomes compared peak itch intensity between the vehicle gel and the active acetaminophen gel treatments during both non-histaminergic itch induction (cowhage) and histaminergic itch induction.^[3]

Safety monitoring: vital signs and laboratory testing

In the healthy adult nasal tolerability study, all adverse events reported by participants were recorded from baseline to day 8.^[1]

Vital signs included change from baseline in blood pressure, measured three times after sitting for 5 minutes using an automated validated device, with the mean of the three readings recorded.^[1]

Pulse was also measured three times after sitting for 5 minutes, with the mean recorded.^[1]

Respiration rate was measured by counting breaths for one minute.^[1]

Oral body temperature was measured, with a reference range described as 35.0°C to 37.5°C.^[1]

Laboratory monitoring included hematology tests such as hemoglobin, hematocrit, red blood cell count (including indices like MCH, MCV, and MCHC), white blood cell count with differential, and platelet count.^[1]

Clinical chemistry included electrolytes (sodium, potassium, chloride, calcium, phosphorous), substrates (BUN, creatinine, total bilirubin, total protein, albumin, uric acid, and C-reactive protein), and enzymes (AST, ALT, ALP, GGT, and CK).^[1]

Virus serology testing included hepatitis B surface antigen, hepatitis B core antibody (IgG + IgM), hepatitis C antibody, and HIV-1 and HIV-2 antibodies.^[1]

Urinalysis included specific gravity, nitrite, protein including microalbuminuria, glucose, ketones, and blood white and red blood cell sediments.^[1]

A urine drug and cotinine screen tested for cotinine and substances including barbiturates, benzodiazepines, amphetamines, cocaine, opiates, and cannabis.^[1]

Pregnancy testing and fertility assessments used a urine dipstick test in this study’s procedures.^[1]

Turner syndrome trial record: Carbomer 980 listed as a gelling agent product

A European trial record about testosterone replacement therapy in women with Turner syndrome lists “CARBOMER 980” as a medicinal product entry described as an eye gel and as a gelling agent, with a stated maximum daily dose amount and maximum treatment period in the record’s product details.^[4]

The same record describes primary endpoints focused on changes in body composition measured by DXA scan (including bone mass, fat mass, and lean muscle mass) and other measures like abdominal circumference and weight.^[4]

It also lists multiple secondary endpoints, including quality of life, inflammatory markers, sexual function, intramuscular sex hormone levels, blood volume and hemoglobin mass, coagulation parameters, metabolic parameters, neurocognitive function, hypothalamus structure, and fitness-related measures such as VO2-max and muscle strength.^[4]

The purpose of the study is to compare how much of the medication is absorbed into the bloodstream from different capsule formulations. Participants will take a single dose of each capsule type while fasting, meaning they will not eat for several hours before taking the medicine, and the study will follow a simple schedule where each dose is given at separate times.

Researchers will watch for any adverse events, which are side effects or unwanted reactions, and will record how often they occur and how severe they are, while also measuring how much of the drug reaches the blood to understand its bioavailability.

Table of Contents

• What is Eneboparatide?
• How Does Eneboparatide Work?
• What Condition Does Eneboparatide Treat?
• Clinical Trial Information
• Potential Benefits
• Administration and Dosage
• Eligibility for Treatment
• Safety Considerations

What is Eneboparatide?

Eneboparatide, also known as AZP-3601, is a new medication being developed to treat chronic hypoparathyroidism^[1]. It is classified as a parathyroid hormone receptor agonist, which means it works by mimicking the action of parathyroid hormone in the body^[2].

How Does Eneboparatide Work?

Eneboparatide is designed to activate the parathyroid hormone receptor, which plays a crucial role in regulating calcium levels in the body. By doing so, it aims to help maintain normal calcium levels in patients with chronic hypoparathyroidism, potentially reducing the need for high doses of calcium and vitamin D supplements^[3].

What Condition Does Eneboparatide Treat?

Eneboparatide is being developed to treat chronic hypoparathyroidism. This is a rare condition where the body doesn’t produce enough parathyroid hormone, leading to low calcium levels and various symptoms. Patients with this condition often require lifelong treatment with calcium and vitamin D supplements^[4].

Clinical Trial Information

Eneboparatide is currently being studied in a Phase 3 clinical trial called CALYPSO. This is an advanced stage of research that aims to confirm the effectiveness and safety of the drug^[5]. The trial is:

• Multicenter: Conducted at multiple hospitals or research centers
• Randomized: Participants are randomly assigned to receive either eneboparatide or a placebo
• Placebo-controlled: Some participants receive an inactive substance for comparison
• Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or placebo

Potential Benefits

The main goals of the eneboparatide treatment being studied are^[6]:

• To eliminate the need for active vitamin D supplements
• To reduce the need for high doses of calcium supplements (aiming for 600 mg/day or less)
• To maintain normal blood calcium levels
• To improve physical and cognitive symptoms associated with hypoparathyroidism
• To enhance overall quality of life for patients

Administration and Dosage

Eneboparatide is administered as a subcutaneous injection, which means it’s injected under the skin. It comes in a pre-filled injection pen, making it potentially easier for patients to self-administer at home^[7]. The maximum daily dose being studied is 100 micrograms, but the optimal dose may vary for each patient^[8].

Eligibility for Treatment

While eneboparatide is still in clinical trials, the study includes adult patients aged 18 to 80 years who have had chronic hypoparathyroidism for at least 12 months. Patients must also be currently taking calcium and vitamin D supplements to manage their condition^[9].

Safety Considerations

As with any medication, there are potential safety considerations. The clinical trial excludes patients with certain conditions or medical histories, such as:

• Recent history of certain cancers
• Severe kidney problems
• Certain heart conditions
• History of bone cancer (osteosarcoma)

It’s important to note that the full safety profile of eneboparatide is still being studied^[10].

Table of Contents

• Trial overview
• Who is being studied
• What the study is measuring
• Study design and treatment groups
• Trial status and size

Trial overview

One authorised Phase 1/2 study is investigating ALN-4324 in people who are overweight to obese, including healthy volunteers and patients with type 2 diabetes mellitus (T2DM).^[1] The study is interventional, which means the research team gives a study treatment and then measures the results.^[1]

Who is being studied

The trial title says it includes overweight to obese healthy volunteers and overweight to obese patients with T2DM.^[1] This means the study is not limited to one group; it is looking at both people without diabetes and people with diabetes in the same weight range.^[1]

The condition listed for the study is type 2 diabetes mellitus.^[1] T2DM is a long-term condition in which the body does not use insulin properly, leading to high blood sugar.

What the study is measuring

The main outcome is the frequency of adverse events, also called AEs.^[1] Adverse events are unwanted medical events that happen during a study, whether or not they are caused by the treatment.

The study also checks safety through vital signs, ECGs, and clinical laboratory assessments.^[1] Vital signs are basic body measurements such as blood pressure and pulse. An ECG is a test that records the heart’s electrical activity.

The brief summary says the study aims to evaluate the safety and tolerability of multiple doses of ALN-4324 in patients with T2DM.^[1] Tolerability means how well people handle the treatment and whether it causes problems that are difficult to accept.

Study design and treatment groups

The trial compares ALN-4324 given subcutaneously with phosphate buffered saline for subcutaneous administration.^[1] Subcutaneous means given under the skin.

The source data does not give detailed participant rules, dose amounts, or the exact schedule of visits.^[1] It does show that the study is focused on early safety evaluation rather than late-stage treatment testing.^[1]

Trial status and size

The trial status is listed as Authorised.^[1] The planned enrolment is 60 people.^[1] Enrolment means the number of participants planned for the study.

Table of Contents

• What is PLS240?
• What condition does PLS240 treat?
• How PLS240 works
• Administration and dosage
• Clinical trials
• Potential benefits
• Safety and side effects
• Who may be eligible for PLS240 treatment?

What is PLS240?

PLS240 is the study name for a new medication called upacicalcet sodium hydrate. It is being developed as a potential treatment for a condition called secondary hyperparathyroidism in people with advanced kidney disease.^[1]

What condition does PLS240 treat?

PLS240 is being studied to treat secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease (ESKD) who are on hemodialysis. Secondary hyperparathyroidism is a common complication in people with kidney failure. It occurs when the parathyroid glands produce too much parathyroid hormone (PTH) in response to low calcium levels in the blood.^[2]

In ESKD, the kidneys can no longer effectively filter waste products from the blood or maintain proper levels of important minerals like calcium and phosphorus. This leads to mineral imbalances that cause the parathyroid glands to become overactive.

How PLS240 works

PLS240 is designed to help control PTH levels in patients with SHPT. While the exact mechanism is not fully described in the trial information, medications for SHPT typically work by mimicking calcium’s effects on the parathyroid glands. This tricks the glands into reducing PTH production.^[3]

Administration and dosage

PLS240 is given as an intravenous injection three times per week after dialysis sessions. The dose is adjusted based on the patient’s PTH and calcium levels. The maximum daily dose being studied is 300 micrograms.^[4]

The medication comes in pre-filled syringes called Poolsep II, which are manufactured by Nipro Corporation in Japan.^[5]

Clinical trials

PLS240 is currently being studied in Phase 3 clinical trials called PATH-1 and PATH-2. These are large studies designed to evaluate how well the medication works and how safe it is in patients with SHPT who are on hemodialysis.^[6]

The trials have two main parts:

1. A double-blind phase lasting 27 weeks, where patients receive either PLS240 or a placebo
2. An open-label extension phase, where all patients receive PLS240 for additional safety monitoring

Potential benefits

The main goals of the PLS240 clinical trials are to see if the medication can:^[7]

• Reduce PTH levels by 30% or more in patients
• Help patients achieve PTH levels within a target range of 150-300 pg/mL
• Improve the balance of calcium and phosphate levels in the blood

If successful, PLS240 could provide a new treatment option for managing SHPT in dialysis patients.

Safety and side effects

As PLS240 is still being studied, all of its potential side effects are not yet known. The clinical trials are closely monitoring patients for any adverse effects, including:^[8]

• Changes in blood calcium levels
• Heart rhythm abnormalities
• Other laboratory test changes

Patients in the trials have regular check-ups, blood tests, and ECGs to watch for any safety concerns.

Who may be eligible for PLS240 treatment?

The clinical trials for PLS240 are enrolling patients who meet specific criteria, including:^[9]

• Adults aged 18-80 years
• Diagnosed with end-stage kidney disease and on hemodialysis for at least 3 months
• Have high PTH levels (above 400 pg/mL) despite current treatments
• Do not have certain other medical conditions that could interfere with the study

It’s important to note that PLS240 is still an investigational medication. It is not yet approved for general use outside of clinical trials. Patients interested in learning more should speak with their kidney specialist about current treatment options for SHPT.

Table of Contents

• What is Tiemonium Methylsulphate?
• Medical Conditions Treated
• Combination with Other Medications
• Administration and Dosage
• Potential Benefits
• Important Considerations

What is Tiemonium Methylsulphate?

Tiemonium Methylsulphate is a medication that belongs to a class of drugs known as anticholinergics. It is also referred to as Tiemonium metilsulfate in some contexts^[1]. This medication is often used in combination with other drugs to treat various medical conditions, particularly those affecting the musculoskeletal system.

Medical Conditions Treated

While the primary focus of the clinical trial data is on a condition called calcium pyrophosphate deposition disease (CPPD), Tiemonium Methylsulphate is being studied in combination with other medications for its potential benefits in treating this condition^[1]. CPPD is a form of arthritis caused by the buildup of calcium pyrophosphate crystals in the joints, leading to inflammation and pain.

Combination with Other Medications

In the clinical trial, Tiemonium Methylsulphate is being studied in combination with Colchicine. This combination is being compared to other treatment options for CPPD, including:

• Methylprednisolone: A corticosteroid used to reduce inflammation
• Colchicine: A medication commonly used to treat gout and other inflammatory conditions
• Hydroxychloroquine: An antimalarial drug also used to treat certain autoimmune diseases
• Methotrexate (MTX): A medication used to treat various inflammatory conditions and certain types of cancer

The combination of these medications is being studied to determine the most effective treatment approach for patients with CPPD^[1].

Administration and Dosage

The specific dosage of Tiemonium Methylsulphate is not provided in the clinical trial data. However, the combination medication (Colchicine with Tiemonium Methylsulphate) is administered as follows:

• 1 mg tablets
• Taken once daily after breakfast
• The dosage may be adjusted to 1 or ½ tablet, depending on individual tolerance

It’s important to note that this dosage information is specific to the clinical trial and may not reflect the typical dosage for all patients^[1].

Potential Benefits

While the specific benefits of Tiemonium Methylsulphate are not directly stated in the clinical trial data, the combination therapy is being studied for its potential to:

• Reduce inflammation in the joints affected by CPPD
• Improve patient-reported outcomes and pain levels
• Decrease calcium crystal deposition in the joints
• Reduce synovitis (inflammation of the synovial membrane in the joints)

These potential benefits are being evaluated through various measures, including changes in pain scores, functional assessments, and imaging studies^[1].

Important Considerations

When considering treatment with Tiemonium Methylsulphate or any medication, it’s essential to keep the following points in mind:

• Always follow your doctor’s instructions regarding dosage and administration.
• Inform your healthcare provider about any other medications you’re taking, as drug interactions may occur.
• Be aware of potential side effects and report any unusual symptoms to your doctor.
• Regular follow-ups and monitoring may be necessary to assess the medication’s effectiveness and safety.

As with any medication, the use of Tiemonium Methylsulphate should be carefully considered by your healthcare provider based on your individual medical history and current condition^[1].

Table of contents

• Trials at a glance
• Type 1 diabetes and cardiovascular risk
• Post-bariatric hypoglycaemia
• Kidney complications in type 1 diabetes
• Hypertrophic cardiomyopathy
• Study designs and endpoints
• Who the studies are for

Trials at a glance

Clinical trials of Sotagliflozin in the source data are being done in four main patient groups: people with type 1 diabetes, people with post-bariatric hypoglycaemia, people with chronic kidney complications linked to type 1 diabetes, and people with hypertrophic cardiomyopathy.^[1][2][3][4]

The trials are authorised and include both Phase 2 and Phase 3 studies.^[1][2][3][4]

The studies are interventional, which means participants receive a study treatment and outcomes are measured over time.^[1][2][3][4]

Type 1 diabetes and cardiovascular risk

One Phase 3 trial is studying a strategy of intensified care in people with type 1 diabetes who are at high risk of cardiovascular disease.^[1]

This study is large, with an enrollment of 2050 people, and it compares a multifactorial intervention strategy with standard care.^[1]

The main outcome is time to the first major adverse cardiovascular event (MACE), which includes non-fatal heart attack, non-fatal stroke, cardiovascular death, or first hospitalization for heart failure.^[1]

The trial also includes safety and efficacy evaluation of 40 mg finerenone in people with type 1 diabetes who are at risk of cardiovascular death and hospitalization for heart failure, but Sotagliflozin is listed among the study interventions in this trial record.^[1]

Post-bariatric hypoglycaemia

The ONSIDE study is a Phase 2 trial of Sotagliflozin for post-bariatric hypoglycaemia, which means low blood sugar that happens after bariatric surgery.^[2]

This study includes 24 participants and uses a randomized, double-blind, placebo-controlled crossover design.^[2]

Participants are people who had Roux-en-Y gastric bypass surgery and have confirmed biochemical post-bariatric hypoglycaemia.^[2]

The main outcome is time spent in level 2 hypoglycaemia, defined in the source as glucose below 3.0 mmol/L, measured by continuous glucose monitoring during the outpatient part of the study.^[2]

Participants receive Sotagliflozin 400 mg once daily and placebo in random order for four weeks each.^[2]

Kidney complications in type 1 diabetes

The PLUTO study is a Phase 2 trial in people with Type 1 Diabetes Mellitus with chronic kidney complications.^[3]

It has an enrollment of 69 participants and compares Sotagliflozin with a matching placebo product.^[3]

The main outcome is the change from baseline to 12 weeks in a dynamic R2*-weighted signal on BOLD MRI, which is used as an indirect measure of renal blood oxygenation.^[3]

The brief summary says the study aims to estimate the effect of three months of Sotagliflozin on renal oxygenation in people with type 1 diabetes and chronic kidney disease.^[3]

Hypertrophic cardiomyopathy

Another Phase 3 trial is studying whether Sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy.^[4]

The listed condition names include obstructive cardiomyopathy, hypertrophic, and non-obstructive hypertrophic cardiomyopathy.^[4]

This study plans to enroll 500 participants and compares Sotagliflozin with placebo.^[4]

The primary outcome is the change from baseline to week 26 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, which measures symptoms and functional limitations.^[4]

Study designs and endpoints

Across the trial records, the main study designs include placebo comparison, crossover treatment, and large Phase 3 testing against standard care or placebo.^[1][2][3][4]

Endpoints, which are the main results the study wants to measure, are different in each trial and match the condition being studied.^[1][2][3][4]

• Cardiovascular outcomes: the type 1 diabetes study measures serious heart and blood vessel events, including heart attack, stroke, cardiovascular death, and heart failure hospitalization.^[1]
• Low blood sugar time: the post-bariatric hypoglycaemia study measures how much time people spend with very low glucose levels.^[2]
• Kidney oxygenation: the kidney study uses MRI-based signals to estimate how well the kidney is oxygenated.^[3]
• Symptom score: the cardiomyopathy study uses a questionnaire score to track symptoms and daily function.^[4]

Who the studies are for

These trials are not for the general public; each one is aimed at a specific patient group described in the source data.^[1][2][3][4]

People in the studies may have type 1 diabetes with high cardiovascular risk, confirmed post-bariatric hypoglycaemia after Roux-en-Y gastric bypass, chronic kidney disease linked to type 1 diabetes, or symptomatic hypertrophic cardiomyopathy.^[1][2][3][4]

In simple terms, the research is trying to learn where Sotagliflozin may help most, and what outcomes should be measured in each disease area.^[1][2][3][4]

Table of contents

• Clinical trials overview
• Turner syndrome study
• Hemodialysis study
• Outcomes and measures
• What patients should know

Clinical trials overview

The provided data include two interventional studies, which means researchers give a treatment and then measure the results.^[1][2]

Both studies are authorised, and both include SODIUM HYDROXIDE as part of the study intervention.^[1][2]

One study is in Phase 2 and the other is in Phase 3, so the research is already testing effects in people rather than only in early lab work.^[1][2]

Turner syndrome study

The first trial is titled Testosterone Replacement Therapy in Women with Turner Syndrome and includes women with Turner syndrome.^[1]

This is a Phase 2 study with an enrollment of 50 participants.^[1]

The brief summary says the study aims to evaluate the endocrine, physiological, cardiovascular, neurocognitive, and genomic effects of transdermal TRT as a supplement to ERT in women with TS.^[1]

In simple words, the study is checking how this treatment may affect hormones, body function, heart and blood vessel health, thinking skills, and genes in this patient group.^[1]

The intervention list includes SODIUM HYDROXIDE together with other ingredients in a transdermal product, which means it is applied through the skin.^[1]

Hemodialysis study

The second trial is titled LOTUS and includes patients with muscle protein turnover issues who are on hemodialysis.^[2]

This is a Phase 3 study with an enrollment of 20 participants.^[2]

The brief summary says the study is designed to look at the effect of IDPN on muscle protein synthesis in chronic hemodialysis patients and to characterize the hemodynamic effects of IDPN.^[2]

The primary outcome is the difference in myofibrillar fractional synthetic rate during one week of treatment with IDPN versus control.^[2]

This means the researchers want to see whether treatment changes the speed at which muscle protein is made, compared with a control group.^[2]

In this trial data, SODIUM HYDROXIDE appears within a combination intervention used in the study setting.^[2]

Outcomes and measures

In the Turner syndrome study, the main outcome is body composition, measured by total body DXA-scan.^[1]

The DXA scan looks at bone mass, visceral fat, subcutaneous fat, lean muscle mass, abdominal circumference, and weight.^[1]

In the hemodialysis study, the main outcome is the myofibrillar fractional synthetic rate, which is a measure of muscle protein building.^[2]

The study also looks at hemodynamic effects, meaning effects on circulation and blood flow.^[2]

What patients should know

These trials are focused on specific groups, so not everyone would be eligible.^[1][2]

One study is for women with Turner syndrome, while the other is for chronic hemodialysis patients with muscle protein turnover concerns.^[1][2]

The data do not describe SODIUM HYDROXIDE as a stand-alone treatment goal; instead, it appears as part of a larger study product or combination.^[1][2]

Because the trials measure specific outcomes, they are designed to answer research questions about how the interventions affect the body in these patient groups.^[1][2]

Table of Contents

• What is Sodium Iodide (131I)?
• Medical Conditions Treated
• How It Works
• Administration and Dosage
• Effectiveness
• Side Effects and Precautions
• Ongoing Research

What is Sodium Iodide (131I)?

Sodium Iodide (131I), also known as radioactive iodine or RAI, is a radioactive form of iodine used in medical treatments^[1]. It is primarily used to treat certain thyroid conditions and thyroid cancer. This medication is available in different forms, including capsules and solutions, and is administered orally^[2].

Medical Conditions Treated

Sodium Iodide (131I) is used to treat several thyroid-related conditions:

• Differentiated Thyroid Cancer (DTC): This includes papillary and follicular thyroid cancers^[1].
• Graves’ Disease: An autoimmune disorder causing hyperthyroidism (overactive thyroid)^[3].
• Graves’ Orbitopathy (GO): An eye condition associated with Graves’ disease^[3].
• Metastatic Thyroid Cancer: Cancer that has spread beyond the thyroid gland^[2].

How It Works

Sodium Iodide (131I) works by targeting thyroid cells, including cancerous ones. The thyroid gland naturally absorbs iodine, and when radioactive iodine is introduced, it is taken up by thyroid cells. The radiation then destroys these cells, effectively treating thyroid cancer or reducing an overactive thyroid^[1][2].

Administration and Dosage

Sodium Iodide (131I) is typically administered orally in the form of capsules or solution. The dosage varies depending on the condition being treated and individual patient factors. For thyroid cancer treatment, doses can range from 3.7 GBq (gigabecquerels) to 7.4 GBq^[1]. In some cases, personalized dosing based on pre-treatment imaging may be used to optimize treatment^[2].

Effectiveness

The effectiveness of Sodium Iodide (131I) treatment can vary depending on the condition:

• For thyroid cancer, it has been shown to be effective in destroying remaining thyroid tissue after surgery and treating metastatic disease^[1].
• In Graves’ disease, it can effectively reduce thyroid function to manage hyperthyroidism^[3].

Ongoing research is exploring ways to optimize treatment effectiveness, such as using pre-treatment imaging to guide dosing^[2].

Side Effects and Precautions

While Sodium Iodide (131I) is generally well-tolerated, it can cause side effects and requires certain precautions:

• Short-term side effects may include nausea, dry mouth, and changes in taste^[1].
• Long-term effects can include an increased risk of developing other cancers, though this risk is generally low^[1].
• Precautions: Patients should avoid close contact with others, especially pregnant women and young children, for a period after treatment due to radiation exposure^[1].
• Women who are pregnant or breastfeeding should not receive this treatment^[3].

Ongoing Research

Several clinical trials are currently exploring ways to improve the use of Sodium Iodide (131I) in treating thyroid conditions:

• A study is comparing systematic radioiodine administration versus a guided approach based on post-operative evaluation in intermediate-risk thyroid cancer patients^[1].
• Another trial is investigating personalized therapy for metastatic thyroid cancer using pre-treatment imaging to optimize dosing^[2].
• Research is also being conducted to compare the effects of radioiodine treatment versus antithyroid drugs in patients with Graves’ disease and active Graves’ orbitopathy^[3].

These studies aim to improve treatment outcomes, minimize side effects, and personalize therapy for individual patients.

Table of Contents

• What is Micronized Progesterone?
• Medical Uses
• Administration
• Effectiveness
• Side Effects and Safety
• Ongoing Research

What is Micronized Progesterone?

Micronized progesterone is a form of the hormone progesterone that has been processed to create very small particles. This micronization process makes the hormone easier for your body to absorb and use^[1]. Progesterone is a naturally occurring hormone in the female body, playing a crucial role in the menstrual cycle and maintaining pregnancy.

Medical Uses

Micronized progesterone is primarily used in the field of reproductive medicine. Its main applications include:

• Assisted Reproductive Technology (ART): It’s used to support the luteal phase (the period after ovulation) during fertility treatments^[1].
• Intrauterine Insemination (IUI): Some studies are investigating its use in IUI treatments^[1].
• In Vitro Fertilization (IVF): It’s commonly used in IVF procedures, particularly in frozen embryo transfer cycles^[2].
• Unexplained Infertility: Research is being conducted on its potential benefits for couples with unexplained infertility^[1].

Administration

Micronized progesterone can be administered in different ways:

• Vaginal Use: The most common form is vaginal capsules or gel. This method allows for direct absorption by the uterus^[1][2].
• Oral Use: In some cases, it may be taken orally, although this is less common in fertility treatments^[2].

The dosage and duration of treatment can vary depending on the specific medical condition and treatment protocol. For example, in some IVF protocols, patients might use 200mg three times daily or 400mg twice daily^[2].

Effectiveness

The effectiveness of micronized progesterone in fertility treatments is an active area of research. Some key points include:

• In IVF treatments, progesterone supplementation is considered standard care and has been shown to improve pregnancy outcomes^[1].
• For IUI treatments, research is ongoing to determine if progesterone supplementation can increase live birth rates^[1].
• In frozen embryo transfer cycles, progesterone is crucial for preparing the uterus for embryo implantation^[2].

Side Effects and Safety

Micronized progesterone is generally considered safe for use in fertility treatments. However, like all medications, it can have side effects. Common side effects may include:

• Drowsiness
• Dizziness
• Abdominal pain
• Nausea
• Breast tenderness

It’s important to note that extensive safety data is available from its use in IVF treatments. Both short-term and long-term assessments of offspring health have not revealed any significant risks associated with progesterone use in reproductive medicine^[1].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of micronized progesterone in various fertility treatments:

• The LUMO study is examining whether progesterone support can improve live birth rates in couples undergoing IUI with mild ovarian stimulation^[1].
• Another study is comparing different formulations and dosages of vaginal micronized progesterone in frozen embryo transfer cycles^[2].
• Researchers are also investigating the impact of progesterone levels on pregnancy outcomes in frozen embryo transfer cycles^[2].

These ongoing studies aim to optimize the use of micronized progesterone in various fertility treatments, potentially improving success rates and patient outcomes.

Table of Contents

• What is Octreotide Hydrochloride?
• Medical Conditions Treated
• How It Works
• Administration
• Efficacy
• Side Effects and Safety
• Ongoing Research

What is Octreotide Hydrochloride?

Octreotide Hydrochloride, also known as CAM2029 or octreotide subcutaneous depot, is a medication used to treat various medical conditions^[1]. It belongs to a class of drugs called somatostatin analogs, which are synthetic versions of a naturally occurring hormone in the body^[2].

Medical Conditions Treated

Octreotide Hydrochloride is used to treat several medical conditions, including:

• Polycystic Liver Disease (PLD): A condition where multiple cysts develop in the liver^[1].
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): A type of cancer that affects the digestive system and pancreas^[2].
• Acromegaly: A hormonal disorder that results from excess growth hormone production^[3].

How It Works

Octreotide Hydrochloride works by mimicking the effects of somatostatin, a natural hormone in the body. It helps to:

• Reduce the production of certain hormones, including growth hormone and insulin-like growth factor 1 (IGF-1)^[3].
• Slow down the growth of tumors in conditions like GEP-NET^[2].
• Potentially reduce the size and symptoms of liver cysts in PLD^[1].

Administration

Octreotide Hydrochloride is administered as a subcutaneous injection, which means it’s injected under the skin^[1][2][3]. The medication is designed as a long-acting depot formulation, which allows for less frequent dosing compared to other forms of octreotide.

In some cases, patients or their partners may be trained to administer the medication at home^[3]. This can provide more convenience and flexibility in treatment.

Efficacy

The effectiveness of Octreotide Hydrochloride varies depending on the condition being treated:

• For PLD, it may help reduce liver volume and improve symptoms related to the disease^[1].
• In GEP-NET, it aims to slow tumor growth and improve progression-free survival^[2].
• For acromegaly, it helps control hormone levels, particularly IGF-1 and growth hormone^[3].

Side Effects and Safety

As with any medication, Octreotide Hydrochloride can cause side effects. Common side effects may include:

• Injection site reactions
• Gastrointestinal symptoms (e.g., nausea, diarrhea)
• Changes in blood sugar levels
• Gallbladder-related issues

It’s important to discuss potential side effects and safety concerns with your healthcare provider^[1][2][3].

Ongoing Research

Several clinical trials are currently underway to further evaluate the efficacy and safety of Octreotide Hydrochloride in various conditions:

• A study is assessing its use in symptomatic polycystic liver disease^[1].
• Another trial is comparing it to existing treatments for gastroenteropancreatic neuroendocrine tumors^[2].
• A long-term safety study is being conducted for patients with acromegaly^[3].

These ongoing studies aim to provide more information about the medication’s effectiveness, optimal dosing, and long-term safety profile.

Table of Contents

• What is Opium, Standardized Powdered?
• Medical Use in Chronic Kidney Disease
• Study Details
• Eligibility Criteria
• Potential Benefits
• Safety Considerations

What is Opium, Standardized Powdered?

Opium, Standardized Powdered is a medicinal substance derived from the opium poppy plant. It is standardized, which means it has a consistent and controlled amount of active ingredients. In the context of this study, it is being used in combination with another medication called colchicine^[1].

Medical Use in Chronic Kidney Disease

The study is investigating the use of opium, standardized powdered, along with colchicine, in patients with moderate chronic kidney disease. Chronic kidney disease is a condition where the kidneys gradually lose their function over time^[1].

The main goal of this research is to see if this combination can help prevent:

• Cardiovascular events: These are problems related to the heart and blood vessels, such as heart attacks or strokes.
• Renal progression: This refers to the worsening of kidney disease over time^[1].

Study Details

The study, known as the COLCHIREN study, is looking at the effectiveness of a low dose (0.5 mg per day) of colchicine combined with opium, standardized powdered. It aims to prevent several types of cardiovascular events in patients with moderate chronic kidney disease, including:

• Cardiovascular death
• Acute coronary syndrome (a term for conditions where blood flow to the heart is suddenly reduced)
• Angina requiring hospitalization (chest pain due to reduced blood flow to the heart)
• Coronary revascularization (procedures to restore blood flow to the heart)
• Transient ischemic attack or non-cardioembolic ischemic stroke (types of “mini-strokes”)
• Peripheral vasculopathy (problems with blood vessels outside the heart and brain)^[1]

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key inclusion criteria are:

• Age between 18 and 99 years
• Moderate chronic kidney disease (with specific measures of kidney function)
• History of a previous cardiovascular event

There are also several exclusion criteria, which include:

• Allergy or intolerance to colchicine
• Current or recent treatment with colchicine
• Recent hospital admission
• Active cancer
• Uncontrolled chronic inflammatory diseases
• Certain infections or liver conditions
• Pregnancy or breastfeeding^[1]

Potential Benefits

The researchers hope that this treatment might:

• Reduce the risk of future cardiovascular events in patients with moderate chronic kidney disease
• Slow down the progression of kidney disease
• Improve markers of inflammation and fibrosis (scarring) in the body^[1]

Safety Considerations

As with any medical treatment, safety is a crucial concern. The study will carefully monitor for any side effects or adverse events. Some specific safety considerations include:

• Avoiding use in patients with certain blood disorders (like low platelet count or anemia)
• Caution in patients taking certain other medications that might interact with the study drug
• Close monitoring of kidney function throughout the study^[1]

It’s important to note that this is a research study, and the benefits and risks of this treatment are still being investigated. Patients should always consult with their healthcare provider before considering participation in any clinical trial.

Table of Contents

• What is METYRAPONE BP?
• Medical Conditions Treated
• How METYRAPONE BP Works
• Administration and Dosage
• Current Clinical Trial
• Eligibility Criteria
• Study Objectives
• Study Endpoints

What is METYRAPONE BP?

METYRAPONE BP is an active substance used in a medication called Metyrapone HRA, which comes in the form of 250mg soft capsules^[1]. It is classified under the ATC code V04CD01, which indicates its use in diagnostic tests related to pituitary function^[2]. The medication is produced by HRA PHARMA RARE DISEASES and is authorized for use in certain countries^[3].

Medical Conditions Treated

METYRAPONE BP is being studied for its potential in treating mild autonomous cortisol secretion in patients with adrenal adenoma^[4]. This condition occurs when a benign tumor (adenoma) on the adrenal gland produces excess cortisol without the typical signs of Cushing’s syndrome. It’s important to note that this use is currently under investigation and may not be an approved indication yet.

How METYRAPONE BP Works

METYRAPONE BP works by affecting the hypothalamus-pituitary-adrenal (HPA) axis, which is responsible for regulating cortisol production in the body^[5]. It inhibits an enzyme involved in cortisol synthesis, potentially helping to reduce excess cortisol levels in patients with autonomous cortisol secretion.

Administration and Dosage

Metyrapone HRA is administered orally in the form of soft capsules^[6]. The maximum daily dose being studied is 6000 mg, but actual dosing would be determined by a healthcare provider based on individual patient needs^[7]. The maximum treatment period under investigation is 12 weeks^[8].

Current Clinical Trial

A clinical trial (number 2024-512100-19-00) is currently investigating the use of METYRAPONE BP in patients with mild autonomous cortisol secretion due to adrenal adenoma^[9]. This study aims to better understand the effects of this condition on cardiometabolic risk factors and chronobiology patterns.

Eligibility Criteria

The study includes specific criteria for participation:

Inclusion Criteria:

• Age over 18 years
• History of an adrenal adenoma
• Morning cortisol levels greater than 1.8 μg/dl following a 1 mg dexamethasone suppression test
• No classical clinical features associated with Cushing’s syndrome

Exclusion Criteria:

• HbA1c greater than 8% or insulin therapy
• Uncontrolled hypertension
• Recent glucocorticoid treatment
• Concomitant medications affecting HPA signaling or CYP3A4 metabolism
• Suspected malignant adrenal tumors
• Severe chronic kidney or liver disease
• Pregnancy or breastfeeding
• MRI contraindications

These criteria ensure that the study focuses on the specific patient group that may benefit from the treatment while minimizing potential risks^[10].

Study Objectives

The main objective of the clinical trial is to perform cardiometabolic phenotyping of patients with autonomous cortisol secretion and identify a disease-specific chronobiology profile in patients with altered HPA axis signaling^[11]. This means the researchers are looking at how this condition affects heart and metabolic health, as well as the body’s natural rhythms.

A secondary objective is to investigate how treatment with metyrapone impacts cardiometabolic risk factors in these patients^[12]. This could provide valuable information on the potential benefits of the medication for this specific condition.

Study Endpoints

The primary endpoint of the study is the measurement of hepatic lipid content (HCL) using a special type of MRI called 1H magnetic resonance spectroscopy^[13]. This will help researchers understand how the condition and treatment affect fat accumulation in the liver.

Secondary endpoints include:

• Insulin secretion and sensitivity
• Body composition and fat distribution
• Heart function and fat accumulation around the heart
• Fat deposition in muscles and heart muscle
• Blood pressure measurements
• Markers of systemic inflammation

These endpoints will provide a comprehensive picture of how autonomous cortisol secretion affects various aspects of health and how treatment with metyrapone might improve these factors^[14].

Table of contents

• Trial overview
• Study design and treatment groups
• Who can participate
• What the trial is measuring
• Trial status and size

Trial overview

The available trial studies MAGNESIUM L-ASPARTATE HYDROCHLORIDE TRIHYDRATE in people with postoperative hypoparathyroidism after thyroid surgery.^[1] The study is called “MAGNEFFICIENT” and it is described as a prospective, randomized, double-blind, placebo-controlled, single-center clinical trial.^[1]

The trial is authorised and is listed as a Phase 3 interventional study.^[1] The brief summary says the study is testing whether 8-day oral magnesium aspartate can reduce chronic postoperative hypoparathyroidism at 6 months.^[1]

Study design and treatment groups

This is a randomized study, which means people are assigned to treatment groups by chance.^[1] It is also double-blind, which means the participants and the study team do not know who receives the active treatment or the placebo during the study.^[1]

The trial compares two oral treatments: TROFOCARD® max and a placebo that has the same composition as the investigational product except for the active substance.^[1] A placebo is a look-alike treatment used to help show whether the study drug makes a real difference.^[1]

Who can participate

The study is focused on people with postoperative hypoparathyroidism after thyroid surgery.^[1] The source data does not give more detailed entry rules, such as age limits or other medical conditions.^[1]

This means the main target population is patients who developed this problem after having their thyroid removed or treated by surgery.^[1]

What the trial is measuring

The main endpoint is the incidence of chronic postoperative hypoparathyroidism 6 months after surgery.^[1] An endpoint is the main result a clinical trial measures to see if the treatment works.^[1]

The trial defines this outcome as persistently low corrected calcium and PTH values when vitamin D or calcium has not been stopped.^[1] Corrected calcium is a blood calcium value adjusted to give a more accurate result, and PTH means parathyroid hormone, which helps control calcium levels.^[1]

Trial status and size

The trial status is Authorised.^[1] The planned enrollment is 500 people, which means the study aims to include 500 participants in total.^[1]

The study is single-center, so it is being carried out at one study site.^[1] This type of design can help keep the study process consistent across all participants.^[1]

Table of Contents

• What is Lidocaine Hydrochloride Monohydrate?
• Medical Uses
• How is it Administered?
• Dosage Information
• Potential Side Effects
• Precautions and Contraindications
• Ongoing Research

What is Lidocaine Hydrochloride Monohydrate?

Lidocaine Hydrochloride Monohydrate is a medication that belongs to a class of drugs called local anesthetics^[1]. It works by blocking nerve signals in your body, which helps to reduce pain and discomfort in specific areas. This drug is commonly known by its shorter name, lidocaine. It’s important to note that lidocaine is different from general anesthetics, which make you unconscious during surgery. Instead, lidocaine keeps you awake but numbs a particular part of your body.

Medical Uses

Lidocaine has several important medical uses:

• Local anesthesia: It’s used to numb specific areas of the body during minor surgical procedures, dental work, or when inserting medical devices^[2].
• Pain relief: Lidocaine can help manage various types of pain, including post-surgical pain and certain chronic pain conditions.
• Cardiac arrhythmias: In some cases, lidocaine is used to treat irregular heartbeats^[2].
• Gastrointestinal issues: Research is being conducted on the use of oral lidocaine to prevent gastrointestinal disturbances in patients after abdominal surgery^[3].

How is it Administered?

Lidocaine can be administered in several ways, depending on its intended use:

• Injection: For local anesthesia, lidocaine is often injected directly into the area that needs to be numbed^[4].
• Topical application: It can be applied to the skin as a cream, ointment, or patch for localized pain relief.
• Intravenous (IV) use: In some medical settings, lidocaine may be given through an IV for certain heart conditions or as part of a pain management strategy^[5].
• Oral form: Some research is exploring the use of oral lidocaine for specific conditions, such as preventing gastrointestinal issues after surgery^[3].

Dosage Information

The dosage of lidocaine varies widely depending on its use, the specific formulation, and individual patient factors. For example:

• For local anesthesia, the dose can range from 1 to 5 mg/kg of body weight^[5].
• In research on oral lidocaine for gastrointestinal issues, doses up to 400 mg per day are being studied^[3].

It’s crucial to emphasize that lidocaine should only be administered by or under the supervision of a healthcare professional. They will determine the appropriate dose based on your specific situation, medical history, and other factors.

Potential Side Effects

Like all medications, lidocaine can cause side effects. Most side effects are mild and temporary, but some can be serious. Common side effects may include:

• Numbness or tingling at the application site
• Mild dizziness or lightheadedness
• Nausea
• Vomiting

More serious side effects, which require immediate medical attention, can include:

• Allergic reactions (rash, itching, swelling)
• Severe dizziness or fainting
• Irregular heartbeat
• Seizures
• Difficulty breathing

It’s important to report any unusual symptoms to your healthcare provider promptly^[6].

Precautions and Contraindications

Certain conditions or factors may affect the use of lidocaine:

• Allergies: If you’re allergic to lidocaine or similar local anesthetics, you should not use this medication.
• Liver or kidney disease: These conditions may affect how your body processes lidocaine.
• Heart conditions: Lidocaine can affect heart rhythm, so it should be used with caution in people with certain heart problems.
• Pregnancy and breastfeeding: The safety of lidocaine during pregnancy and breastfeeding should be discussed with a healthcare provider.

Always inform your healthcare provider about all medications you’re taking, including over-the-counter drugs and supplements, as they may interact with lidocaine^[6].

Ongoing Research

Lidocaine is being studied for various potential uses beyond its current applications. Some areas of ongoing research include:

• Gastrointestinal issues: A study is investigating the use of oral lidocaine to prevent gastrointestinal disturbances in patients after abdominal surgery^[3].
• Pain management: Researchers are exploring new ways to use lidocaine for managing different types of pain, including chronic pain conditions.
• Combination therapies: Studies are looking at how lidocaine might work in combination with other medications to enhance pain relief or reduce side effects.

These research efforts aim to expand our understanding of lidocaine’s potential benefits and optimize its use in medical care. However, it’s important to remember that research findings may not immediately translate into new approved uses, and any new applications would need to go through rigorous testing and regulatory approval processes before becoming widely available.

Table of Contents

• Overview of the clinical trials
• Trials in adults with obesity
• Trials in children with obesity
• Trials in healthy volunteers
• Trial in type 2 diabetes
• Main outcomes and what they mean

Overview of the clinical trials

The provided trial data show research on Liraglutide in several groups, mainly people with obesity and children with obesity, plus healthy volunteers and people with type 2 diabetes.^[1][2][3][4] The studies are in Phase 2 and Phase 3, which means they are testing effects in research settings and comparing outcomes in larger groups.^[1][2][3][4] The main goals are to measure changes in body weight, BMI, hunger, stomach activity, and blood sugar control.^[1][2][3][4]

Trials in adults with obesity

One Phase 2 study, NCT2024-513679-42-00, enrolled 255 adults with obesity or overweight and was completed.^[1] It compared multiple dose levels of PF-07976016 against placebo in participants with obesity on a background of liraglutide, and it also included Saxenda as a study treatment listed in the data.^[1] The main outcome was the percent change in body weight at Week 16.^[1]

This study is important because it focuses on whether adding another study medicine can change weight more than placebo in people already receiving liraglutide-based background treatment.^[1] The trial was interventional, which means researchers gave the study treatments and then measured the effects.^[1]

Trials in children with obesity

One Phase 3 study, NCT2023-508504-38-00, is authorised and includes 82 children aged 6 to under 12 years with obesity.^[3] The study compares Liraglutide 3.0 mg once daily with placebo for weight management in this age group.^[3] The main outcome is the relative change in BMI from Week 0 to Week 56.^[3]

This trial is focused on a younger population, so it helps answer whether the study treatment can support weight-related care in children with obesity.^[3] The use of BMI change as the main outcome shows that the trial is measuring growth-related weight patterns over time, not just short-term change.^[3]

Trials in healthy volunteers

Another Phase 3 study, NCT2024-518641-21-00, is authorised and includes 15 healthy volunteers.^[2] It studies the effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings, and ad libitum food intake.^[2] The main outcome is to detect changes in MMC activity after administration of liraglutide compared with placebo.^[2]

This type of study does not focus on a disease group alone; instead, it helps researchers observe how the study treatment affects digestive patterns and hunger in people without the target condition.^[2] The trial uses saline as the placebo comparison and measures several body responses at once.^[2]

Trial in type 2 diabetes

The provided data also include a large Phase 3 study, NCT05433584, in 781 adult participants with type 2 diabetes.^[4] In this trial, Liraglutide appears among several treatment options in a study comparing tirzepatide with intensified conventional care.^[4] The main outcome is the change from baseline in HbA1c.^[4]

This study is not only about one medicine, but it still shows that liraglutide is part of the treatment list being studied in people with type 2 diabetes.^[4] HbA1c is a key diabetes measure because it reflects average blood sugar over time.^[4]

Main outcomes and what they mean

Across these trials, the main outcomes are practical measures that matter to patients and researchers.^[1][2][3][4] The obesity studies look at body weight and BMI, which are common ways to track weight change.^[1][3] The healthy volunteer study looks at stomach movement, hunger, and food intake, which helps show how the body responds after treatment.^[2] The diabetes study uses HbA1c, which helps show longer-term blood sugar control.^[4]

The trial data also show different study sizes, from 15 healthy volunteers to 781 people in the diabetes study.^[2][4] This range suggests that the research questions are different: some studies are small and focused on body responses, while others are larger and compare treatment effects in broader patient groups.^[1][2][3][4]

Table of Contents

• Trial overview
• Study design and phase
• Who can participate
• What is being measured
• Trial details

Trial overview

The clinical trial data show one study that includes Lixisenatide as part of treatment for adults with type 2 diabetes.^[1] The study is named SURPASS-EARLY and is an interventional trial, which means researchers are comparing treatment plans rather than just observing people.^[1]

Study design and phase

This trial is a Phase 3 study.^[1] Phase 3 trials are later-stage studies that test treatments in larger groups and compare how well they work.^[1] The trial is authorised and includes 781 participants.^[1]

Who can participate

The trial is designed for adult participants with type 2 diabetes.^[1] The source data do not list more detailed entry rules, so the main target group is adults living with this condition.^[1]

What is being measured

The main outcome is the change from baseline in Hemoglobin A1c (HbA1c).^[1] HbA1c is a blood test that shows average blood sugar over time, so it helps researchers see how well treatment controls diabetes.^[1] The brief summary says the study aims to show that tirzepatide is non-inferior to intensified conventional care for HbA1c change from baseline to Week 104.^[1] Non-inferior means the treatment is not worse than the comparison by more than a set amount.^[1]

Trial details

The trial compares tirzepatide with intensified conventional care, which means stronger standard diabetes treatment.^[1] The intervention list also includes several other diabetes medicines and treatment options, such as semaglutide, dulaglutide, exenatide, liraglutide, sitagliptin, and Lixisenatide.^[1] The data provided do not explain the exact role of each listed treatment arm, but they show that Lixisenatide is one of the treatments included in this comparison study.^[1]

The study follows participants for 104 weeks, which is about 2 years.^[1] This long follow-up helps researchers see how treatment effects change over time.^[1]

In simple terms, this trial is trying to learn whether the study treatment plan can control blood sugar as well as, or better than, standard care in adults with type 2 diabetes.^[1]

Table of Contents

• What is it?
• How does it work?
• What is it used for?
• Vaccines containing this strain
• Ongoing research
• Safety and effectiveness

What is it?

INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) – LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED is a component used in influenza vaccines. This is a specific strain of the influenza virus that has been inactivated (killed) so it cannot cause infection. It is designed to protect against a particular type of influenza A virus, specifically the H3N2 subtype^[1].

How does it work?

When this inactivated virus strain is included in a vaccine, it helps your immune system recognize and fight against similar live viruses if you’re exposed to them. The vaccine stimulates your body to produce antibodies against this specific strain of influenza, providing protection without causing the actual illness^[1].

What is it used for?

This strain is used in vaccines to prevent influenza infection, particularly in older adults. Influenza, commonly known as the flu, is a respiratory illness that can cause severe complications, especially in vulnerable populations like the elderly^[1].

Vaccines containing this strain

This strain is found in several influenza vaccines, including:

• Efluelda: A high-dose quadrivalent influenza vaccine for older adults^[1].
• Vaxigriptetra: A standard-dose quadrivalent influenza vaccine^[1].
• Vaxigrip Tetra: Another quadrivalent influenza vaccine^[2].

These vaccines are typically given as an injection into the muscle (intramuscular injection)^[1][2].

Ongoing research

Current research is focusing on comparing the effectiveness of different vaccine formulations:

• A study is comparing high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD) in older adults. The main goal is to see if the high-dose vaccine is better at reducing hospitalizations due to influenza or pneumonia^[1].
• Another study is investigating whether influenza vaccination can help preserve beta cell function in young patients with newly diagnosed type 1 diabetes^[2].

Safety and effectiveness

The vaccines containing this strain are approved for use and considered safe for most people. However, as with any medical treatment, there are some considerations:

• People with severe allergies to eggs, chicken proteins, or previous allergic reactions to influenza vaccines should not receive these vaccines without consulting their doctor^[2].
• The vaccines may not be suitable for people with certain medical conditions or those taking specific medications. Always consult with your healthcare provider before getting vaccinated^[2].
• The effectiveness of the vaccine can vary from year to year, depending on how well the vaccine strains match the circulating viruses^[1].

Remember, while this strain is an important component of influenza vaccines, it’s just one part of a complex formula designed to protect against multiple strains of the flu virus. Always follow your healthcare provider’s advice regarding vaccinations.

Table of Contents

• Introduction
• What is Gallium (68Ga)?
• How Does It Work?
• Medical Conditions Diagnosed Using Gallium (68Ga)
• Benefits of Gallium (68Ga) Imaging
• The Imaging Procedure
• Safety and Side Effects
• Conclusion

Introduction

Gallium (68Ga) is an innovative diagnostic tool that is being studied for its potential to improve the detection and assessment of various medical conditions. This article will provide an overview of Gallium (68Ga), its uses, and what patients can expect when undergoing imaging procedures using this substance.

What is Gallium (68Ga)?

Gallium (68Ga) is a radioactive isotope of gallium that is used in medical imaging. It is typically combined with other substances to create specialized imaging agents. These agents are designed to target specific tissues or processes in the body, allowing doctors to visualize and assess various medical conditions^[1].

How Does It Work?

Gallium (68Ga) works by emitting positrons, which are detected by a special camera in a PET (Positron Emission Tomography) scanner. When combined with specific targeting molecules, Gallium (68Ga) can be directed to bind to certain types of cells or tissues in the body. This allows doctors to create detailed images of these areas and detect abnormalities that might not be visible with other imaging techniques^[2].

Medical Conditions Diagnosed Using Gallium (68Ga)

Research is ongoing to explore the potential of Gallium (68Ga) in diagnosing and assessing various medical conditions. Some of the areas being studied include:

• Cancer: Gallium (68Ga) is being investigated for its ability to detect and stage different types of cancer, including:
  • Gastro-esophageal cancer
  • Breast cancer
  • Prostate cancer
  • Multiple myeloma
  • Rectal cancer
• Crohn’s Disease: Researchers are studying the use of Gallium (68Ga) to assess the healing of perianal fistulas in patients with Crohn’s disease^[3].
• Primary Aldosteronism: Gallium (68Ga) imaging is being evaluated for its potential to identify unilateral adrenal secretion of aldosterone in patients with this condition^[4].

Benefits of Gallium (68Ga) Imaging

Gallium (68Ga) imaging offers several potential benefits:

• Improved detection: It may be more sensitive in detecting certain types of cancer or other abnormalities compared to conventional imaging techniques.
• Better staging: For cancer patients, it could provide more accurate information about the extent of the disease, helping doctors plan the most appropriate treatment.
• Non-invasive: The imaging procedure is non-invasive, requiring only an injection of the imaging agent.
• Personalized medicine: By providing detailed information about a patient’s condition, it could help doctors tailor treatments more effectively^[5].

The Imaging Procedure

If you are scheduled for a Gallium (68Ga) imaging procedure, here’s what you can expect:

1. You will receive an injection of the Gallium (68Ga) imaging agent through an intravenous (IV) line.
2. There will be a waiting period to allow the imaging agent to circulate through your body and accumulate in the target tissues. This can take anywhere from a few minutes to a couple of hours, depending on the specific procedure.
3. You will then lie on a table that moves through a PET scanner. The scanner detects the radiation emitted by the Gallium (68Ga) and creates detailed images of your body.
4. The scanning process usually takes about 30-60 minutes.
5. After the scan, you can typically resume your normal activities, but you may be advised to drink plenty of water to help flush the radioactive material from your system^[6].

Safety and Side Effects

Gallium (68Ga) imaging is generally considered safe. The amount of radiation exposure is relatively low and the body eliminates the radioactive material quickly. However, as with any medical procedure, there are some considerations:

• Pregnant women should not undergo this procedure due to potential risks to the fetus.
• Breastfeeding women may need to temporarily stop breastfeeding after the procedure.
• Some people may experience mild side effects such as pain at the injection site, nausea, or headache, but these are typically rare and short-lived^[7].

Conclusion

Gallium (68Ga) imaging is an exciting area of medical research that holds promise for improving the diagnosis and management of various conditions, particularly in oncology. As research continues, it may become an increasingly important tool in personalized medicine, helping doctors to provide more accurate diagnoses and tailored treatments. If you’re scheduled for a Gallium (68Ga) imaging procedure, don’t hesitate to discuss any questions or concerns with your healthcare provider.

Table of Contents

• What is Fluasterone?
• What is Cushing’s Syndrome?
• How Fluasterone May Help
• Ongoing Research
• Potential Benefits
• Who Might Be Eligible for Fluasterone Treatment?
• Safety Considerations

What is Fluasterone?

Fluasterone is a new medication being studied for its potential to help people with Cushing’s syndrome, especially those who have high blood sugar levels as a result of this condition. It comes in the form of a buccal tablet, which means it’s designed to be placed between your gum and cheek where it slowly dissolves.^[1]

What is Cushing’s Syndrome?

Cushing’s syndrome is a hormonal disorder caused by high levels of a hormone called cortisol in your body for a long time. This can lead to various health problems, including weight gain, high blood pressure, and high blood sugar (which can lead to diabetes).^[1]

How Fluasterone May Help

Researchers are studying Fluasterone to see if it can help control high blood sugar (also called hyperglycemia) in adults with Cushing’s syndrome. They think it might be able to improve how the body handles sugar, which could be very helpful for people with this condition who often struggle with diabetes or pre-diabetes.^[1]

Ongoing Research

A clinical trial is currently underway to test Fluasterone. This study is called a “Double-Blind, Placebo-Controlled, Crossover Pilot Study”. Here’s what this means:

• Double-Blind: Neither the patients nor the doctors know who is getting the real medicine and who is getting a placebo (a dummy pill with no active ingredient).
• Placebo-Controlled: Some patients will receive Fluasterone, while others will receive a placebo. This helps researchers determine if Fluasterone is truly effective.
• Crossover: Patients will switch between Fluasterone and placebo during different parts of the study. This allows each patient to serve as their own control, which can make the results more reliable.
• Pilot Study: This is an early-stage study to gather initial data on how well Fluasterone works and how safe it is.^[1]

Potential Benefits

The researchers are looking at several potential benefits of Fluasterone:

1. Blood Sugar Control: The main goal is to see if Fluasterone can help lower blood sugar levels in people with Cushing’s syndrome.
2. Lipid Profile Improvement: They’re also checking if it can help improve cholesterol and other fat levels in the blood.
3. Body Composition Changes: The study will look at whether Fluasterone affects body fat distribution, which is often altered in Cushing’s syndrome.
4. Liver Health: Some patients with Cushing’s syndrome develop fatty liver disease. The study will check if Fluasterone has any effect on this.^[1]

Who Might Be Eligible for Fluasterone Treatment?

The study is looking for adults aged 18-75 who have been diagnosed with Cushing’s syndrome and also have either impaired glucose tolerance (pre-diabetes) or type 2 diabetes. However, there are many specific criteria for who can and can’t participate in the study. For example:

• Participants must have certain test results that confirm Cushing’s syndrome.
• Their diabetes must not be too severe (HbA1c less than 9%).
• They can’t have certain other health conditions or be taking certain medications.^[1]

Safety Considerations

As with any new medication, safety is a top priority. The study will carefully monitor participants for any side effects or safety concerns. Some things they’ll be watching for include:

• How well patients tolerate the medication
• Any changes in heart rhythm
• Liver and kidney function
• Potassium levels in the blood

It’s important to note that Fluasterone is still in the research phase. It’s not yet approved for general use, and we don’t know all of its potential side effects or long-term impacts. That’s why careful studies like this one are so important.^[1]

Table of Contents

• What is FLUOROESTRADIOL F-18?
• How is it used?
• Who can benefit from FLUOROESTRADIOL F-18?
• Current Clinical Trials
• How is FLUOROESTRADIOL F-18 administered?
• Safety Considerations

What is FLUOROESTRADIOL F-18?

FLUOROESTRADIOL F-18, also known as 18F-FES or 16α-18F-fluoro-17β-oestradiol, is a diagnostic tool used in medical imaging^[1]. It’s a radioactive substance that helps doctors see specific areas in your body using a special type of scan called PET/CT (Positron Emission Tomography/Computed Tomography)^[2].

How is it used?

FLUOROESTRADIOL F-18 is primarily used to help diagnose and manage a specific type of breast cancer. It works by attaching to estrogen receptors in the body, which are often found in high numbers in certain breast cancers. When used with a PET/CT scan, it can show doctors where these receptors are located, helping them to:

• Determine if the cancer has spread to other parts of the body
• Guide treatment decisions
• Monitor how well the treatment is working

Who can benefit from FLUOROESTRADIOL F-18?

This diagnostic tool is specifically designed for patients with:

• Metastatic breast cancer: Cancer that has spread from the breast to other parts of the body^[1]
• ER-positive breast cancer: Cancer cells that have estrogen receptors on their surface^[1]
• HER2-negative breast cancer: Cancer cells that don’t have high levels of a protein called HER2^[1]

It’s particularly useful for patients who have already undergone initial treatment and are experiencing a relapse or progression of their disease^[2].

Current Clinical Trials

FLUOROESTRADIOL F-18 is currently being studied in clinical trials to further understand its benefits. Two notable studies are:

1. The ECLECTIC Trial: This study is looking at how FLUOROESTRADIOL F-18 PET/CT scans, along with other tests, can help guide treatment decisions for patients whose cancer has progressed after initial therapy^[1].
2. The ESTROTIMP Trial: This trial is investigating how FLUOROESTRADIOL F-18 PET/CT scans might impact treatment management for patients with metastatic breast cancer who have relapsed after their first line of treatment^[2].

How is FLUOROESTRADIOL F-18 administered?

FLUOROESTRADIOL F-18 is given as an intravenous injection (into a vein) before a PET/CT scan^[1]. The dose is typically measured in units called megabecquerels (MBq), with a maximum dose of about 400 MBq^[1]. The exact dose may vary based on your body weight, usually around 4 MBq per kilogram of body weight^[2].

Safety Considerations

While FLUOROESTRADIOL F-18 is generally considered safe, there are some important points to consider:

• It should not be used in patients with known allergies to any of its components^[2].
• It’s not recommended for use in pregnant or breastfeeding women^[1].
• Patients with severe liver or kidney problems may need special consideration^[2].
• As with any medical procedure involving radiation, the benefits should outweigh the potential risks.

Always discuss any concerns or questions with your healthcare provider. They can provide more detailed information based on your specific medical history and condition.

Table of Contents

• What is FLUOROETHYLTYROSINE F-18?
• Medical Conditions
• How It Works
• Administration
• Comparison with Other Diagnostic Tools
• Eligibility for the Study
• Study Objectives

What is FLUOROETHYLTYROSINE F-18?

FLUOROETHYLTYROSINE F-18, also known as FET, is a diagnostic tool used in medical imaging^[1]. It is a radioactive tracer used in a type of imaging test called PET (Positron Emission Tomography) scan. This substance is specifically designed to help doctors visualize and assess brain tumors more accurately.

Medical Conditions

FET is used to diagnose and monitor several types of brain conditions^[1]:

• Newly diagnosed cerebral gliomas: These are tumors that start in the glial cells of the brain, which support and protect nerve cells.
• Recurrent cerebral gliomas: This refers to gliomas that have come back after initial treatment.
• Brain metastases: These are cancer cells that have spread to the brain from primary tumors in other parts of the body.

How It Works

FLUOROETHYLTYROSINE F-18 works by accumulating in brain tumor cells more than in normal brain tissue^[1]. When a patient undergoes a FET-PET scan:

1. The radioactive tracer is injected into the patient’s bloodstream.
2. The tracer travels to the brain and concentrates in tumor cells.
3. A special camera detects the radioactive signals from the tracer.
4. Computers create detailed 3D images of the brain, showing where the tracer has accumulated.

This process helps doctors to see the size, location, and activity of brain tumors more clearly than with standard imaging techniques.

Administration

FLUOROETHYLTYROSINE F-18 is given as an intravenous injection, which means it’s injected directly into a vein^[1]. The maximum daily dose is 185 MBq (megabecquerels), which is a unit used to measure radioactivity. The total maximum dose for the entire treatment period is 222 MBq.

Comparison with Other Diagnostic Tools

A current study is comparing FET-PET scans with another type of PET scan that uses a tracer called Fluciclovine-18F (also known as FACBC)^[1]. This comparison aims to determine which tracer is more effective in diagnosing and monitoring brain tumors. The study is looking at factors such as:

• Agreement on tumor size and tracer distribution
• Correlation of tumor-to-brain ratios
• Ability to differentiate between tumor progression and treatment-related changes
• Time-to-peak and slope of time-activity curves in different types of brain tumors

Eligibility for the Study

To participate in the study comparing FET and FACBC, patients must meet certain criteria^[1]:

• Be at least 18 years old
• Have the mental and physical ability to understand and comply with the study requirements
• Have decision-making capacity and be able to give informed consent
• Be referred for a FET-PET scan of the brain by their treating physician
• Have a suspected glioma before biopsy or surgery, or suspected tumor recurrence after previous treatment for cerebral glioma or brain metastasis

Patients who are pregnant, breastfeeding, have uncontrolled epilepsy, or are unable to lie still for 40 minutes are not eligible for the study.

Study Objectives

The main objectives of the current study involving FLUOROETHYLTYROSINE F-18 are^[1]:

1. To assess the agreement between FET-PET and FACBC-PET in terms of tumor size and tracer distribution.
2. To determine the correlation of tumor-to-brain ratios in FET and FACBC PET scans.
3. To compare the accuracy of FET and FACBC PET in differentiating tumor progression from treatment-related changes in recurrent gliomas and brain metastases.
4. To analyze differences in time-to-peak and slope of time-activity curves between FET and FACBC uptake in high-grade and low-grade gliomas, as well as in tumor progression and treatment-related changes.

These objectives aim to provide valuable information about the effectiveness of FLUOROETHYLTYROSINE F-18 as a diagnostic tool for brain tumors, potentially improving the accuracy of diagnosis and monitoring of these conditions.

Table of Contents

• What is ETHANOL (96 PER CENT)?
• Medical Use in Shoulder Surgery
• Clinical Trial: OPRICA Study
• Application and Dosage
• Patient Eligibility
• Potential Benefits
• Precautions and Side Effects

What is ETHANOL (96 PER CENT)?

ETHANOL (96 PER CENT) is a form of highly concentrated alcohol. It’s also known by several other names, including:

• Alcohol (96%)
• Ethanol 96%
• Ethyl alcohol 96%
• Ethanol 96% (V/V)

This substance is commonly used in medical settings for its antiseptic properties, meaning it can kill or slow the growth of microorganisms on the skin.^[1]

Medical Use in Shoulder Surgery

In the context of shoulder surgery, ETHANOL (96 PER CENT) is being studied as part of a skin preparation solution. It’s combined with another substance called povidone-iodine to create an antiseptic solution. This combination is used to clean the skin before surgery to reduce the risk of infection.^[1]

Clinical Trial: OPRICA Study

A clinical trial called OPRICA (Optimization of skin preparation to reduce Cutibacterium acnes colonization in superficial and deep samples during prosthetic shoulder surgery in male patients) is currently studying the use of this ethanol-based solution. The main goals of this study are:

1. To evaluate how effective a 5% alcoholic iodine povidone solution is at reducing bacteria on the skin before shoulder surgery.^[1]
2. To compare this method with another approach using a different substance called benzoyl peroxide.^[1]

The study focuses on a specific type of bacteria called Cutibacterium acnes, which is commonly found on human skin and can cause infections after shoulder surgery.^[1]

Application and Dosage

In the OPRICA study, the ethanol-based solution (BETADINE ALCOOLIQUE 5%) is applied to the skin just before surgery. It’s used as a single-dose cutaneous solution, which means it’s applied directly to the skin in the area where the surgery will be performed.^[1]

Patient Eligibility

The study is specifically looking at male patients who are having shoulder surgery. Some key eligibility criteria include:

• Patients without a history of previous shoulder surgery on the operated shoulder
• Patients undergoing specific types of shoulder joint replacement surgeries
• Patients who are covered by social security
• Patients who have given informed consent to participate in the study^[1]

There are also several conditions that would make a patient ineligible for the study, such as having certain skin conditions, ongoing infections, or allergies to the substances used.^[1]

Potential Benefits

The main potential benefit of using this ethanol-based solution is reducing the risk of infection after shoulder surgery. The study aims to determine:

• How effective the solution is at reducing bacteria on the skin
• Whether it can help prevent infections for up to 2 years after surgery
• How it compares to other methods of skin preparation^[1]

Precautions and Side Effects

While the study is still ongoing and full results are not yet available, there are some general precautions to be aware of:

• The solution is for external use only and should not be ingested
• Patients with known allergies or sensitivities to iodine or alcohol should inform their healthcare provider
• The study is monitoring for any skin irritation or other adverse reactions to the solution^[1]

Table of Contents

• What is CLOFUTRIBEN?
• What is Polymyalgia Rheumatica (PMR)?
• How CLOFUTRIBEN Works
• Clinical Trial Details
• Eligibility Criteria
• Potential Benefits of CLOFUTRIBEN
• Safety Considerations

What is CLOFUTRIBEN?

CLOFUTRIBEN, also known as SPI-62 or ASP3662, is a new medication being studied for the treatment of polymyalgia rheumatica (PMR). It is currently in Phase II clinical trials, which means it is being tested to determine its effectiveness and safety in patients with PMR.^[1]

CLOFUTRIBEN comes in the form of a film-coated tablet that is taken orally (by mouth). The medication is being developed by Sparrow Pharmaceuticals, Inc.^[1]

What is Polymyalgia Rheumatica (PMR)?

Polymyalgia rheumatica (PMR) is a medical condition that causes muscle pain and stiffness, usually in the shoulders, upper arms, and hips. It primarily affects older adults and is often treated with corticosteroids like prednisolone. PMR can significantly impact a person’s quality of life, making everyday activities difficult.^[1]

How CLOFUTRIBEN Works

While the exact mechanism of action is not fully described in the provided information, CLOFUTRIBEN is being studied in combination with prednisolone, a commonly used corticosteroid for PMR treatment. The main objectives of the study are:

1. To determine if the prednisolone dose needs to be adjusted when given with CLOFUTRIBEN to maintain its effectiveness in treating PMR.^[1]
2. To observe if CLOFUTRIBEN can reduce the side effects (toxicity) of prednisolone in PMR patients.^[1]
3. To understand how CLOFUTRIBEN works in the body of PMR patients.^[1]
4. To assess the safety of CLOFUTRIBEN when used alongside prednisolone in PMR treatment.^[1]

Clinical Trial Details

The clinical trial for CLOFUTRIBEN is designed to test different combinations of the drug with prednisolone. Here’s a simplified breakdown of the trial structure:

• The trial is divided into different groups (cohorts) of patients.
• All patients start on a stable dose of 10 mg prednisolone daily.
• Different cohorts receive varying doses of CLOFUTRIBEN (ranging from 0.6 mg to 6 mg daily) and prednisolone (10 mg to 30 mg daily).
• The treatment period lasts for 28 days, with patients receiving CLOFUTRIBEN for two weeks and a placebo (a pill with no active ingredient) for two weeks.
• Patients don’t know when they’re receiving CLOFUTRIBEN or the placebo, which helps ensure unbiased results.
• After the treatment period, there’s a follow-up visit about a month later.^[1]

Eligibility Criteria

To participate in the CLOFUTRIBEN clinical trial, patients must meet certain criteria. Here are some key points:

Inclusion criteria (requirements to join the study):

• Diagnosed with PMR according to specific medical criteria
• No current PMR relapse (worsening of symptoms)
• Taking a stable dose of 10 mg prednisolone daily for at least a week before starting the trial^[1]

Exclusion criteria (reasons a person cannot join the study):

• Any reason why they can’t take prednisolone
• Diagnosis or symptoms of giant cell arteritis (a related inflammatory condition)
• Other autoimmune diseases besides PMR
• Use of certain other medications that might interfere with the study
• History of a condition called endogenous hypercortisolism (where the body produces too much cortisol)^[1]

Potential Benefits of CLOFUTRIBEN

While the full benefits of CLOFUTRIBEN are still being studied, the researchers hope to find that it can:

• Improve the effectiveness of prednisolone in treating PMR symptoms
• Reduce the side effects associated with prednisolone use
• Potentially allow for lower doses of prednisolone while maintaining symptom control^[1]

Safety Considerations

As with any new medication, the safety of CLOFUTRIBEN is a crucial aspect of the clinical trial. The researchers will be closely monitoring participants for any side effects or adverse reactions. Some key points about safety:

• The trial includes a placebo period to help distinguish between effects of CLOFUTRIBEN and those of prednisolone alone.
• Participants will have regular check-ups and tests to monitor their health throughout the trial.
• The researchers will be looking at various health markers, including blood tests for inflammation levels and tests to check how the body is processing sugars.^[1]

It’s important to note that as CLOFUTRIBEN is still in the testing phase, not all potential side effects or long-term impacts are known. This is why careful monitoring and follow-up are crucial parts of the clinical trial process.

Table of Contents

• Introduction
• What is B/PHUKET/3073/2013-LIKE VIRUS?
• Role in Influenza Vaccines
• Clinical Trials and Research
• Safety and Effectiveness
• Conclusion

Introduction

Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. To protect against this disease, scientists develop vaccines that target specific strains of the virus. One such component used in many influenza vaccines is the B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE). This article will explore what this virus is, its role in vaccines, and the ongoing research involving it.^[1]

What is B/PHUKET/3073/2013-LIKE VIRUS?

The B/PHUKET/3073/2013-LIKE VIRUS is a strain of influenza B virus. It was first isolated in Phuket, Thailand in 2013, hence its name. This virus belongs to the B/Yamagata lineage, which is one of the two main lineages of influenza B viruses that commonly circulate among humans.^[2]

In vaccine development, this virus is often referred to as a “wild type” strain. This means it’s a naturally occurring form of the virus, as opposed to a modified or laboratory-created version. The term “LIKE” in its name indicates that the vaccine may contain either this exact strain or a very similar one that produces the same immune response.

Role in Influenza Vaccines

The B/PHUKET/3073/2013-LIKE VIRUS is a crucial component in many influenza vaccines, particularly in quadrivalent (four-strain) vaccines. These vaccines typically include two influenza A strains and two influenza B strains to provide broader protection against circulating flu viruses.^[3]

When included in a vaccine, this virus strain helps the immune system develop antibodies that can recognize and fight off similar influenza B viruses if the person is exposed to them. This process, known as immunogenicity, is key to how vaccines protect against disease.

Clinical Trials and Research

Several clinical trials have been conducted or are ongoing to study vaccines containing the B/PHUKET/3073/2013-LIKE VIRUS. These studies aim to evaluate the effectiveness, safety, and immune response generated by these vaccines in different populations. For example:

• A Phase 3 randomized trial is comparing a high-dose quadrivalent influenza vaccine (which includes this virus strain) to a standard-dose vaccine in older adults. The study aims to evaluate the relative vaccine effectiveness in reducing hospitalizations for influenza or pneumonia.^[4]
• Another study is investigating the effect of influenza vaccination, including this strain, on preserving beta cell function in patients with early type 1 diabetes.^[5]
• Researchers are also studying the immunogenicity and safety of co-administering an ExPEC9V vaccine with a high-dose quadrivalent influenza vaccine containing this strain in adults aged 65 years or older.^[6]

Safety and Effectiveness

Vaccines containing the B/PHUKET/3073/2013-LIKE VIRUS have generally been found to be safe and effective. However, like all medical treatments, they can have side effects. Common side effects may include:

• Pain, redness, or swelling at the injection site
• Fatigue
• Headache
• Muscle aches
• Fever (less common)

It’s important to note that these side effects are typically mild and short-lived. Serious allergic reactions are rare but can occur. People with severe allergies to eggs or any components of the vaccine should consult their healthcare provider before getting vaccinated.^[7]

Conclusion

The B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE) plays a significant role in many current influenza vaccines. As a component of quadrivalent flu vaccines, it helps provide protection against a common strain of influenza B virus. Ongoing research continues to evaluate its effectiveness in different populations and in combination with other vaccines. While generally safe and effective, as with any medical treatment, it’s important to discuss any concerns or questions with a healthcare provider.

Table of contents

• Clinical trial overview
• Who the trials include
• Trial phases and study design
• Main endpoints being measured
• Key trial details
• Summary of the listed trials

Clinical trial overview

The available studies of ATUMELNANT are focused on congenital adrenal hyperplasia, including classic congenital adrenal hyperplasia.^[1][2][3] These are interventional studies, which means participants receive a study treatment so researchers can measure its effects.^[1][2][3]

All three listed trials are currently Authorised.^[1][2][3] The studies are looking at safety, tolerability, and whether ATUMELNANT can help control adrenal hormone levels while lowering the need for glucocorticoid treatment.^[1][2][3]

Who the trials include

The trial set includes both adult participants and pediatric participants.^[2][3] The pediatric study is designed for children and adolescents with classic congenital adrenal hyperplasia, while the adult study is for adults with the same disease.^[2][3]

The Phase 2 trial is broader in its condition wording and includes participants with congenital adrenal hyperplasia.^[1] The trial records do not provide more detailed age or eligibility rules, so only the population named in each study can be stated here.^[1][2][3]

Trial phases and study design

ATUMELNANT is being studied across Phase 2, Phase 3, and Phase 4 trials.^[1][2][3] Phase 2 usually helps researchers learn more about safety and early effectiveness, Phase 3 is a larger confirmatory stage, and Phase 4 is a later study stage that can add more information after earlier testing.^[1][2][3]

The Phase 2 study plans to enroll 150 participants, the Phase 4 pediatric study plans to enroll 156 participants, and the Phase 3 adult study plans to enroll 140 participants.^[1][2][3] This range shows that the program includes both mid-size and larger studies.^[1][2][3]

Main endpoints being measured

The studies mainly measure safety and efficacy, which means how well the treatment works.^[1][2][3] Safety outcomes include treatment-emergent adverse events, serious adverse events, and adverse events that lead to stopping treatment.^[1][2]

Some safety endpoints also look at glucocorticoid deficiency, adrenal insufficiency, adrenal crisis, and hospitalizations related to congenital adrenal hyperplasia.^[1] These terms describe important medical problems that can happen when the body does not have enough adrenal hormone support or when the disease becomes severe.^[1]

The main efficacy measure in the Phase 2 trial is the change from baseline in morning serum A4 over time.^[1] In the pediatric Phase 4 study, one part looks at the change from baseline in morning A4 at Week 8, another part looks at the percent change in daily glucocorticoid dose at Week 28 while serum early morning A4 stays at or below the upper limit of normal, and another part again measures change in morning A4 over time.^[2]

The adult Phase 3 study measures the proportion of participants with morning post-glucocorticoid A4 at or below the upper limit of normal who are on physiologic glucocorticoid replacement at Week 32.^[3] In simple terms, this asks how many participants can keep hormone levels controlled while using a replacement dose of glucocorticoid that is intended to be close to normal body needs.^[3]

Key trial details

The Phase 2 study is titled “A study to learn about the safety and effectiveness of CRN04894 on participants,” and it is listed under congenital adrenal hyperplasia.^[1] Its brief summary says the main safety objective is to evaluate safety and tolerability, and the main efficacy objective is to evaluate change from baseline in serum androstenedione (A4).^[1]

The pediatric Phase 4 study is titled “A Study in Pediatric Participants with Congenital Adrenal Hyperplasia,” and it focuses on classic congenital adrenal hyperplasia.^[2] Its brief summary says the study wants to evaluate safety and tolerability in pediatric participants, and also whether ATUMELNANT can reduce daily glucocorticoid dose while keeping adrenal androgen levels normalized.^[2]

The adult Phase 3 study is titled “A Study to Evaluate Atumelnant in Adults with Congenital Adrenal Hyperplasia,” and it also focuses on classic congenital adrenal hyperplasia.^[3] Its brief summary says the study compares ATUMELNANT with placebo to see whether it can reduce daily glucocorticoid dosage while maintaining adrenal androgen control at the end of the 32-week treatment period.^[3]

The intervention records show oral tablet forms for ATUMELNANT in the pediatric and adult studies, with tablet strengths listed in the source data.^[2][3] The source data also names a 120 mg oral dose in the Phase 2 study.^[1]

Summary of the listed trials

Table of contents

• Trial overview
• Who can participate
• Study design and phase
• What is being measured
• Trial context and treatments listed
• Patient-friendly terms

Trial overview

The source data include one clinical trial that lists Alogliptin in the treatment set for adults with type 2 diabetes.^[1] The study is identified as NCT05433584 and is titled “A Study of Tirzepatide Compared with Intensified Conventional Care in Adult Participants with Type 2 Diabetes (SURPASS-EARLY).”^[1]

The trial status is Authorised, and the study type is Interventional, which means researchers are assigning treatments and measuring the results.^[1]

Who can participate

The target population in the trial is adult participants with type 2 diabetes.^[1] The source does not provide more detailed entry rules, such as exact age limits, lab values, or other health conditions.^[1]

• Adults: people who are old enough to join an adult study group.^[1]
• Type 2 diabetes: the condition being studied in this trial.^[1]

Study design and phase

The trial is in Phase 3, which is a later stage of clinical research.^[1] Phase 3 studies usually look at how well a treatment works in a larger group of people and continue to collect important safety and effectiveness information.^[1]

The enrollment is listed as 781, meaning 781 participants are included or planned for the study.^[1]

What is being measured

The primary outcome is change from baseline in Hemoglobin A1c (HbA1c).^[1] HbA1c is a blood test that shows average blood sugar over about 2 to 3 months.^[1] “Baseline” means the starting measurement before treatment begins.^[1]

The brief summary states that the study aims to show that tirzepatide is non-inferior to intensified conventional care for HbA1c change from baseline to Week 104.^[1] Non-inferior means the new treatment is not worse than the comparison treatment by more than a set amount.^[1]

Trial context and treatments listed

The intervention list in the source includes many diabetes medicines, including Alogliptin, along with other listed treatments such as sitagliptin, linagliptin, semaglutide, tirzepatide, dulaglutide, exenatide, liraglutide, lixisenatide, saxagliptin, vildagliptin, pioglitazone, metformin, and metformin with sulfonamides.^[1]

Some entries in the intervention list are shown as “-” with a dose and route, which likely reflects comparator or placeholder treatment entries in the source record, but the source does not explain them further.^[1]

For patients reading the trial record, the most important point is that Alogliptin appears in a study focused on diabetes treatment comparison and blood sugar control, not as a standalone drug monograph.^[1]

Patient-friendly terms

Interventional study means researchers give a treatment and then watch what happens.^[1] Primary outcome means the main result the study is built to measure.^[1] Week 104 means the study looks at results after 104 weeks, or about 2 years.^[1]

Intensified conventional care means standard treatment that is adjusted more closely or more strongly to improve diabetes control.^[1] This helps researchers compare how the study treatment performs against usual care that has been stepped up.^[1]

Table of contents

• Trial overview
• Who can participate
• What is being measured
• Trial status and design

Trial overview

The available study is a Phase 2 trial of ALXN2420 in people with acromegaly, a condition being studied in adults.^[1] It is an interventional study, which means researchers assign the study treatment and compare results over time.^[1]

The trial compares ALXN2420 with placebo, which is a look-alike treatment with no active study drug, and both are given together with somatostatin analogs.^[1] The somatostatin analogs listed in the trial are octreotide acetate and lanreotide acetate.^[1]

Who can participate

This study is designed for adult participants with acromegaly.^[1] The brief summary says the treatment is being tested in adults who are already receiving somatostatin analog therapy.^[1]

The trial includes a planned enrollment of 60 participants.^[1] This number shows how many people the researchers planned to include in the study.^[1]

What is being measured

The main endpoint, or main result the study wants to measure, is the percentage change from baseline in serum IGF-1 level at Week 15.^[1] Baseline means the starting value before treatment begins, and serum IGF-1 is a blood marker used to follow disease activity in acromegaly.^[1]

The brief summary states that the purpose of the study is to evaluate whether 15 weeks of ALXN2420 treatment can lower IGF-1 levels better than placebo when used with SSA therapy.^[1] SSA therapy means treatment with somatostatin analogs.^[1]

Trial status and design

The trial status is Suspended, so the study is not actively moving forward at the time shown in the source data.^[1] The study is listed as interventional and uses a comparison between ALXN2420 and matching placebo.^[1]

Only one trial was provided in the source data, so this article focuses on that single Phase 2 study in acromegaly.^[1]

Table of contents

• Trial overview
• Who is being studied
• Study phase and design
• What is being measured
• Treatments in the study
• What the trial aims to show

Trial overview

The clinical trial listed for Albiglutide is NCT05433584, an interventional study in adults with type 2 diabetes.^[1] It is shown as Phase 3 and has a status of Authorised.^[1] The planned enrollment is 781 participants.^[1]

Who is being studied

This study is focused on adult participants with type 2 diabetes.^[1] The trial data do not list the full eligibility rules, so the exact entry criteria are not available here.^[1]

Study phase and design

The study is a Phase 3 trial, which usually means a larger study that compares treatment options and checks how well they work in real patient groups.^[1] It is also described as an interventional study, meaning researchers are testing treatments and measuring the results.^[1]

What is being measured

The main outcome is the change from baseline in hemoglobin A1c (HbA1c).^[1] HbA1c is a blood test that shows average blood sugar over time, so it helps researchers see whether treatment improves diabetes control.^[1] The study brief says the goal is to show that tirzepatide is non-inferior to intensified conventional care in HbA1c change from baseline to Week 104 in participants with type 2 diabetes.^[1]

Treatments in the study

The intervention list includes Albiglutide at 50 mg by injection, along with several other diabetes medicines and treatment options used for comparison in the study.^[1] These include sitagliptin, linagliptin, tirzepatide, semaglutide, exenatide, dulaglutide, liraglutide, lixisenatide, saxagliptin, pioglitazone, metformin, vildagliptin, and alogliptin, as well as some unnamed comparator entries in the trial record.^[1]

What the trial aims to show

The trial record is centered on comparing treatment effects in type 2 diabetes, with HbA1c as the key measure of success.^[1] For patients, this means the study is trying to learn whether the treatment strategy being tested can control blood sugar well over a long period, up to Week 104.^[1]

Table of Contents

• What is A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN?
• Role in Influenza Vaccines
• Clinical Trials and Research
• Effectiveness and Immune Response
• Safety Profile
• Use in Special Populations
• Conclusion

What is A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN?

A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215) is a specific strain of the influenza A virus used in the development of flu vaccines^[1]. This strain is derived from the H1N1 subtype of influenza A, which was responsible for the 2009 swine flu pandemic. The “PDM09” in its name refers to this pandemic origin.

Influenza viruses are constantly evolving, which is why flu vaccines are updated regularly. This particular strain was isolated in Victoria, Australia in 2019 and has been selected for inclusion in recent flu vaccines due to its representation of currently circulating H1N1 viruses.

Role in Influenza Vaccines

This strain is a key component in many quadrivalent (four-strain) influenza vaccines. It’s included to provide protection against H1N1 influenza A viruses that are similar to this strain. Quadrivalent vaccines typically contain:

• Two influenza A strains (including this H1N1 strain)
• Two influenza B strains

The A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN is found in various flu vaccine formulations, including:

• Standard-dose quadrivalent vaccines (like Vaxigrip Tetra and Influvac Tetra)^[2]
• High-dose quadrivalent vaccines (like Efluelda)^[3]

Clinical Trials and Research

Several clinical trials have been conducted or are ongoing to evaluate vaccines containing this strain:

• A study comparing high-dose and standard-dose quadrivalent influenza vaccines in adults aged 65 and older^[4]
• Research on the effectiveness of influenza vaccines in patients with hematological cancers^[5]
• Trials evaluating new mRNA-based influenza vaccines that include this strain^[6]

These studies aim to assess the immunogenicity (ability to provoke an immune response) and safety of vaccines containing this strain in various populations.

Effectiveness and Immune Response

The effectiveness of vaccines containing the A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN is typically measured by looking at:

• Seroconversion rates: The percentage of people who develop a significant increase in antibodies after vaccination
• Geometric mean titers (GMTs): A measure of the average antibody levels in a group of vaccinated individuals

Clinical trials have shown that vaccines containing this strain can elicit a strong immune response in many individuals. However, the strength of the response can vary based on factors such as age, overall health, and the specific vaccine formulation used^[7].

Safety Profile

Vaccines containing the A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN have generally demonstrated a good safety profile in clinical trials. Common side effects may include:

• Pain, redness, or swelling at the injection site
• Headache
• Fatigue
• Muscle aches

These side effects are typically mild and resolve within a few days. Serious adverse events are rare^[8].

Use in Special Populations

Research has been conducted on the use of vaccines containing this strain in various populations, including:

• Older adults (65 years and above)
• Patients with hematological cancers
• Individuals with chronic medical conditions

These studies aim to ensure that the vaccine is safe and effective in populations that may be at higher risk for influenza complications^[9].

Conclusion

A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215) is an important component of current influenza vaccines, providing protection against circulating H1N1 influenza A viruses. Ongoing research continues to evaluate its effectiveness and safety in various populations and vaccine formulations. As with all influenza vaccines, it’s important to receive annual vaccination to ensure protection against the most current strains.

Table of Contents

• Introduction
• What is SPI-62?
• How Does SPI-62 Work?
• Conditions Treated by SPI-62
• Clinical Trials
• Potential Benefits of SPI-62
• Possible Side Effects
• Conclusion

Introduction

SPI-62, also known as Clofutriben, is a novel medication currently being studied for the treatment of various conditions related to excessive cortisol levels in the body. This article will provide an overview of SPI-62, its mechanism of action, and the ongoing clinical trials investigating its potential benefits for patients with Cushing’s syndrome and other related disorders.

What is SPI-62?

SPI-62 is a new drug developed by Sparrow Pharmaceuticals, Inc. Its chemical name is 4-{5-[2-(4-chloro-2,6-difluorophenoxy)propan-2-yl]-4-methyl-4H-1,2,4-triazol-3-yl}-3-fluorobenzamide^[1]. It is also known by other names such as Clofutriben and ASP3662^[2]. SPI-62 is administered orally as a film-coated tablet.

How Does SPI-62 Work?

SPI-62 is a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1)^[1]. HSD-1 is an enzyme that plays a crucial role in converting inactive cortisone to active cortisol in the body. By inhibiting this enzyme, SPI-62 aims to reduce the excessive cortisol levels associated with various medical conditions, particularly Cushing’s syndrome.

Conditions Treated by SPI-62

SPI-62 is being investigated for the treatment of several conditions related to excessive cortisol levels:

• Cushing’s Syndrome: A hormonal disorder caused by prolonged exposure to high levels of cortisol^[1].
• ACTH-dependent Cushing’s Syndrome: Including Cushing’s disease, ectopic ACTH secretion, and ectopic corticotrophin-releasing hormone (CRH) secretion^[1].
• Hypercortisolism related to benign adrenal tumors: Excessive cortisol production due to autonomous cortisol secretion (ACS) from benign adrenal lesions^[2].
• Polymyalgia Rheumatica (PMR): A inflammatory disorder that causes muscle pain and stiffness, often treated with corticosteroids like prednisolone^[3].

Clinical Trials

Several clinical trials are currently underway to evaluate the safety and efficacy of SPI-62:

1. ACTH-dependent Cushing’s Syndrome Trial: This study aims to characterize the pharmacologic effect of SPI-62 in patients with ACTH-dependent Cushing’s syndrome, including Cushing’s disease and ectopic ACTH/CRH secretion^[1].
2. Hypercortisolism Related to Benign Adrenal Tumor Trial: This trial is studying the benefit-risk profile of SPI-62 in patients with complications due to hypercortisolism related to autonomous cortisol secretion (ACS) from benign adrenal tumors^[2].
3. Polymyalgia Rheumatica (PMR) Trial: This study is investigating the use of SPI-62 in combination with prednisolone for patients with PMR, aiming to determine if SPI-62 can help reduce the required dose of prednisolone while maintaining efficacy and potentially reducing side effects^[3].

Potential Benefits of SPI-62

The ongoing clinical trials are exploring several potential benefits of SPI-62:

• Reduction of excessive cortisol levels in patients with Cushing’s syndrome and related conditions^[1].
• Improvement in various symptoms and complications associated with hypercortisolism, such as hyperglycemia, dyslipidemia, hypertension, and osteoporosis^[1][2].
• Potential to reduce the required dose of corticosteroids (like prednisolone) in conditions such as PMR, which may help minimize side effects associated with long-term corticosteroid use^[3].
• Possible improvements in mood, cognition, and overall quality of life for patients with cortisol-related disorders^[1].

Possible Side Effects

As SPI-62 is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are closely monitoring for any adverse events, including:

• Changes in hypothalamic-pituitary-adrenal (HPA) axis function^[1].
• Effects on the hypothalamic-pituitary-gonadal (HPG) axis^[1].
• Any unexpected changes in laboratory values, vital signs, or other clinical parameters^[1][2].

It’s important to note that the safety profile of SPI-62 will be more clearly understood as the clinical trials progress and more data becomes available.

Conclusion

SPI-62 (Clofutriben) represents a promising new approach to treating conditions associated with excessive cortisol levels, such as Cushing’s syndrome and related disorders. By inhibiting the enzyme responsible for converting inactive cortisone to active cortisol, SPI-62 aims to address the root cause of these conditions. Ongoing clinical trials will provide more information about its efficacy, safety, and potential benefits for patients. As research continues, SPI-62 may offer new hope for individuals struggling with the challenging symptoms and complications of cortisol-related disorders.